Bibliography

 MANUSCRIPT PUBLICATIONS

1.      Watkins E, Chow CM, Lingohr-Smith M, Lin J, Yong C, Tangirala K, Collins K, Li J, Brooks R, Amico J. Bacterial vaginosis treatment patterns, associated complications, and healthcare economic burden of women with Medicaid coverage in the United States. Ann Pharmacother. 2023; In press.

2.      Di Fusco M, Vaghela S, Moran MM, Lin J, Atwell JE, Malhotra D, Scassellati Sforzolini T, Cane A, Nguyen JL, McGrath LJ. COVID-19-associated hospitalizations among children less than 12 years of age in the United States. J Med Econ. 2022;25:334-346.

3.      Di Fusco M, Lin J, Vaghela S, Lingohr-Smith M, Nguyen JL, Scassellati Sforzolini T, Judy J, Cane A, Moran MM. COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies. Expert Rev Vaccines. 2022;21:435-451.

4.      Zhang Q, O’Hara M, McCormick C, Lingohr-Smith M, Borentain S, Mathews M, Joshi K, Anjo J, Lin J. Patient profiles, initial hospital encounter characteristics, and hospital re-encounters of patients with a hospital emergency department visit or inpatient admission for major depressive disorder. J Med Econ. 2022;25:172-181.

5.      McComsey GA, Lingohr-Smith M, Rogers R, Lin J, Donga P. Real-world adherence to antiretroviral therapy among HIV-1 patients across the United States. Adv Ther. 2021;38:4961-4974.

6.      Aly A, Lingohr-Smith M, Lin G, Seal B. Locoregional therapy patterns and healthcare economic burden of patients with hepatocellular carcinoma in the USA. Hepat Oncol. 2021;8:HEP37.

7.      Neslusan C, Voelker J, Lingohr-Smith M. Lin J. Characteristics of hospital encounters and associated economic burden of patients with major depressive disorder and acute suicidal ideation or behavior. Hosp Pract (1995). 2021;49:176-183.

8.  Di Fusco M, Shea KM, Lin J, Nguyen JL, Angulo FJ, Benigno M, Malhotra D, Emir B, Sung AH, Hammond JL, Stoychev S, Charos A. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. J Med Econ. 2021;24:308-317.

9. Deitelzweig S, Dhamane AD, Di Fusco M, Russ C, Rosenblatt L, Lingohr-Smith M, Lin J. Utilization of anticoagulants and predictors of treatment among hospitalized patients with atrial fibrillation in the USA. J Med Econ. 2020;23:1389-1400.

10.   Fermann, GJ, Lovelace B, Christoph MJ, Lingohr-Smith M, Lin J, Deitelzweig SB. Major bleed costs of atrial fibrillation patients treated with factor Xa inhibitor anticoagulants. J Med Econ. 2020;23:1409-1417.

11.   Deitelzweig SB, Lovelace B, Christoph M, Lingohr-Smith M, Lin J, Fermann GJ. Evaluation of the incremental healthcare economic burden of patients with atrial fibrillation treated with direct-acting oral anticoagulants and hospitalized for major bleeds in the USA. Adv Ther. 2020;37:3942-3953.

12.   Deitelzweig S, Baker CL, Dhamane AD, Mardekian J, Dina O, Rosenblatt L, Russ C, Poretta T, Lingohr-Smith M, Lin J. Comparison of readmissions among hospitalized nonvalvular atrial fibrillation patients treated with oral anticoagulants in the United States. J Drug Assess. 2020;9:87-96.

13.   Deitelzweig S, Hlavacek P, Mardekian J, Rosenblatt L, Russ C, Tuell K, Lingohr-Smith M, Lin J, Guo JD. Comparison of inpatient admission rates of patients treated with apixaban vs. warfarin for venous thromboembolism in the emergency department. Hosp Pract (1995). 2020;48:41-48.

14.   Baker CL, Dhamane AD, Rajpura J, Mardekian J, Dina O, Russ C, Rosenblatt L, Lingohr-Smith M, Lin J. Switching to another oral anticoagulant and drug discontinuation among elderly patients with nonvalvular atrial fibrillation treated with different direct oral anticoagulants. Clin Appl Thromb Hemost. 2019;25:1076029619870249.

15.   Dhamane AD, Baker CL, Rajpura J, Mardekian J, Dina O, Russ C, Rosenblatt L, Lingohr-Smith M, Lin J. Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients. Curr Med Res Opin. 2019;35:1769-1776.

16.   Amin A, Deitelzweig S, Bucior I, Lin J, Lingohr-Smith M, Menges B, Neuman WR. Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US. J Med Econ. 2019;22:1119-1125.

17.   Lin J, Szukis H, Sheehan JJ, Alphs LA, Menges B, Lingohr-Smith M, Benson C. Economic burden of treatment-resistant depression among patients hospitalized for major depressive disorder in the United States. Psychiatr Res Clin Pract. 2019;1(2):68-76.

18.   Jabbour EJ, Mendiola MF, Lingohr-Smith M, Lin J, Makenbaeva D. Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US. J Med Econ. 2019;22:1113-1118.

19.   Feldman SR, Wu JJ, Armstrong AW, Lebwohol M, Jacobson AA, Lingohr-Smith M, Lin J. Evaluating costs of biologic drugs for the treatment of moderate-to-severe psoriasis in the United States. J Psoriasis Psoriatic Arthritis. Published Online April 29, 2019.  https://doi.org/10.1177/2475530319842174.

20.   Amin A, Neuman WR, Lingohr-Smith M, Menges B, Lin J. Venous thromboembolism prophylaxis and risk for acutely medically ill patients stratified by different ages and renal disease status. Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029618823287.

21.   Amin A, Neuman WR, Lingohr-Smith M, Menges B, Lin J. Influence of the duration of hospital length of stay on frequency of prophylaxis and risk for venous thromboembolism among patients hospitalized for acute medical illnesses in the USA. Drugs Context. 2019;8:212568.

22.   Baker CL, Dhamane AD, Mardekian J, Dina O, Russ C, Rosenblatt L, Lingohr-Smith M, Menges B, Lin J, Nadkarni A. Comparison of drug switching and discontinuation rates in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants in the United States. Adv Ther. 2019;36:162-74.

23.   Amin A, Neuman WR, Lingohr-Smith M, Menges B, Lin J. Venous thromboembolism prophylaxis and risk in the inpatient and outpatient continuum of care among hospitalized acutely ill patients in the US: a retrospective analysis. Adv Ther. 2019;36:59-71.

24.   Patil SA, Flasar MH, Lin J, Lingohr-Smith M, Skup M, Wang S, Chao J, Cross RK. Reduced imaging radiation exposure and costs associated with anti-tumor necrosis factor therapy in Crohn's disease. Dig Dis Sci. 2019;64:60-67.

25.   Deitelzweig S, Guo D, Hlavacek P, Lin J, Wygant G, Rosenblatt L, Gupta A, Pan X, Mardekian J, Lingohr-Smith M, Menges B, Marshall A, Nadkarni A. Hospital resource utilization and costs associated with warfarin versus apixaban treatment among patients hospitalized for venous thromboembolism in the United States. Clin Appl Thromb Hemost. 2018;24(Suppl 9):261S-268S.

26.   Jabbour EJ, Siegartel LR, Lin J, Lingohr-Smith M, Menges B, Makenbaeva D. Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model. J Med Econ. 2018;21:1036-40.

27.   Feldman SR, Rastogi S, Lin J. Effect of prior biologic use on cost-effectiveness of brodalumab vs. ustekinumab for treatment of moderate-to-severe psoriasis in the United States. Dermatol Ther (Heidelb). 2018;8:441-453.

28.   Jabbour EJ, Siegartel LR, Lin J, Lingohr-Smith M, Menges B, Makenbaeva D. Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States. Leuk Lymphoma. 2018;20:1-7.

29.   Dasta JF, Sundar S, Chase S, Lingohr-Smith M, Lin J. Economic impact of tolvaptan treatment vs. fluid restriction based on real-world data among hospitalized patients with heart failure and hyponatremia. Hosp Pract (1995). 2018;46:197-202.

30.   Wu JJ, Feldman SR, Rastogi S, Menges B, Lingohr-Smith M, Lin J. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. J Dermatolog Treat. 2018;29:769-74.

31.   Feldman SR, Wu JJ, Rastogi S, Menges B, Lingohr-Smith M, Lin J. The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans. J Med Econ. 2018;21:537-41.

32.   Law A, Liao L, Lin J, Yaldo A, Lynen R. Twelve-month discontinuation rates of levonorgestrel intrauterine system 13.5 mg and subdermal etonogestrel implant in women aged 18-44: A retrospective claims database analysis. Contraception. 2018 Apr 21. pii: S0010-7824(18)30142-2. doi: 10.1016/j.contraception.2018.04.006.

33.   Wen L, Divers C, Lingohr-Smith M, Lin J, Ramsey S. Improving quality of care in oncology through healthcare payment reform. Am J Manag Care. 2018;24:e93-e98.

34.   Carney PI, Yao J, Lin J, Law A. Occurrence of chronic pelvic pain, abnormal uterine bleeding, and hysterectomy postprocedure among women who have undergone female sterilization procedures: a retrospective claims analysis of commercially insured women in the US. J Min Invas Gynecol. 2018;25:651-60.

35.   Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, Hlavacek P, Lingohr-Smith M, Menges B, Lin J. All-cause, stroke/systemic embolism-, and major bleeding-related healthcare costs among elderly nonvalvular atrial fibrillation patients treated with oral anticoagulants. Clin Appl Thromb Haemost. 2018;24:602-11.

36.   Deitelzweig S, Evan M, Trocio J, Gupta K, Lingohr-Smith M, Menges B, Lin J. Impact of warfarin persistence on health-care utilization and costs among atrial fibrillation patients managed in anticoagulation clinics in the US. Clin Appl Thromb Hemost. 2018;24:364-71.

37.   Schwartz DA, Wang A, Ozbay B, Skup M, Eichner SF, Lin J, Chao J. Comparison of health care utilization and costs between patients with perianal fistulizing Crohn's disease treated with biologics with or without previous seton placement. Inflamm Bowel Dis. 2017;23:1860-6.

38.   Lin J, Trocio J, Gupta K, Mardekian J, Lingohr-Smith M, Menges B, You M, Nadkarni A. Major bleeding risk and healthcare economic outcomes of nonvalvular atrial fibrillation patients newly initiated with oral anticoagulant therapy in the real-world setting. J Med Econ. 2017;20:952-61.

39.   Law A, Yu JS, Wang W, Lin J, Lynen R. Trends and regional variations in provision of contraception methods in a commercially insured population in the United States based on nationally proposed measures. Contraception. 2017;96:175-82.

40.   Jabbour EJ, Lin J, Siegartel LR, Lingohr-Smith M, Menges B, Makenbaeva D. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase. J Med Econ. 2017;20:1007-12.

41.   Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, Lingohr-Smith M, Menges B, Lin J. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2017;33:1745-54.

42.   Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, Lingohr-Smith M, Menges B, Lin J. Effect of apixaban versus warfarin use on health care resource utilization and costs among elderly patients with nonvaluvular atrial fibrillation. J Manag Care Spec Pharm. 2017;23:1191-1201.

43.   Deitelzweig S, Neuman WR, Lingohr-Smith M, Menges B, Lin J. Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors. J Med Econ. 2017;20:1217-23.

44.   Umpierrez GE, O'Neal D, DiGenio A, Goldenberg R, Hernandez-Triana E, Lin J, Park CY, Renard E, Kovatchev. Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes. Diabetes Obes Metab. 2017;19:1317-21.

45.   Carney PI, Yao J, Lin J, Law A. Comparison of healthcare costs among commercially insured women in the United States who underwent hysteroscopic sterilization versus laparoscopic bilateral tubal ligation sterilization. J Womens Health (Larchmt). 2017;25:483-90.

46.   Law A, McCoy M, Lingohr-Smith M, Lin J, Lynen R. Modeled cost differences associated with use of levonorgestrel intrauterine devices. Am J Pharm Benefits. 2017;9:12-16. Available at: https://ajpblive.s3.amazonaws.com/_media/_pdf/AJPB_0102_2017_Law%20(final).pdf

47.   Law A, Yu J, Lin W, Lynen R, Lin J. Evaluation of hospitalization costs and associated factors among maternity stays involving low-risk and moderate- to high-risk childbirths in the United States. Hosp Pract (1995). 2017;45:230-37.

48.   Lin J, Siegartel LR, Lingohr-Smith M, Menges B, Makenbaeva D. Using health care claims data to assess the prevalence of Hodgkin lymphoma and relapsed or refractory Hodgkin lymphoma in the US. Clin Ther. 2017;39:303-310.

49.   Porcellati F, Lin J, Lucidi P, Bolli GB, Fanelli CG. Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials. Medicine (Baltimore). 2017;96:e6022.

50.   Blonde L, Chava P, Dex T, Lin J, Nikonova EV, Goldenberg RM. Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials. Diabetes Obes Metab. 2017;19:275-283.

51.   Lin J, Lingohr-Smith M, Fan T. Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist combination therapy among patients with type 2 diabetes in the US. ClinicoEconomics Outcomes Res 2017;9:19-29.

52.   Divers EC, Platt D, Wang ECY, Lin J, Lingohr-Smith M, Mathai SC. A review of clinical trial endpoints of patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension and how they relate to patient outcomes in the U.S. J Manag Care Spec Pharm. 2017;23:92-104.

53.   Spyropoulos AC, Preblick R, Kwong WJ, Lingohr-Smith M, Lin J. Is adherence to the American College of Chest Physicians recommended anticoagulation treatment duration associated with different outcomes among patients with venous thromboembolism? Clin Appl Thromb Hemost. 2017;23:532-41.

54.   Joshi K, Lin J, Lingohr-Smith M, Fu DJ, Muser, E. Treatment patterns and antipsychotic medication adherence among commercially-insured patients with schizoaffective disorder in the US. J Clin Psychopharmacol. 2016;36:429-35.

55.   Law A, McCoy M, Lingohr-Smith M, Lin J, Lynen R. Modeled cost differences associated with use of levonorgestrel intrauterine devices. Am J Pharm Ben. 2017;9:12-16.

56.   Lee B, Trence D, Inzucchi S, Lin J, Haimowitz S, Wilkerson E, Williams C, Mosier M, Dex T. Improving type 2 diabetes patient health outcomes with individualized continuing medical education for primary care. Diabetes Ther. 2016;7:473-81.

57.   Yabe D, Ambos A, Cariou B, Duvnjak L, Evans M, González-Gálvez G, Lin J, Nikonova EV, de Pablos-Velasco P, Yale JF, Ahrén B. Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials. J Diabetes Complications. 2016;30:1385-92.

58.   Carney P, Lin J, Xia F, Law A. Temporal trend in the use of hysteroscopic sterilization vs laparoscopic sterilization and characteristics of commercially insured and Medicaid-insured women in the US who had the procedures. Int J Women's Health. 2016;8:137-44.

59.   Deitelzweig S, Bruno A, Trocio J, Tate N, Gupta K, Lin J, Lingohr-Smith M. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. Curr Med Res Opin. 2016;32:573-82.

60.   Lin J, Zhou S, Wei W, Pan C, Lingohr-Smith M, Levin P. Does clinical inertia vary by personalized A1c goal? A study of predictors and prevalence of clinical inertia in a U.S. managed-care setting. Endocr Pract. 2016;22:151-61.

61.   Deitelzweig, S, Evans M, Hillson E, Trocio J, Bruno A, Tan W, Lingohr-Smith M, Singh P, Lin J. Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation. Curr Med Res Opin. 2016;32:87-94.

62.   Law A, Wen L, Lin J, Tangirala M, Schwartz JS, Zampaglione E. Are women benefiting from the Affordable Care Act? A real-world evaluation of the impact of the Affordable Care Act on out-of-pocket costs for contraceptives. Contraception. 2016;93:392-7.

63.   Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M. Estimate of real-world medical costs avoidance when new oral anticoagulants are used vs. standard therapy for the treatment of patients with venous thromboembolism in the U.S. Clin Appli Thromb Hemost. 2016;22:5-11.

64.   Jabbour E, Makenbaeva D, Lingohr-Smith M, Lin J. Impact of genetic mutations and health plan access to therapies on treatment response and drug costs related to tyrosine kinase inhibitor treatment among patients with chronic myelogenous leukemia. Am J Clin Oncol. 2015. Nov 17

65.   Jabbour E, Makenbaeva D, Lingohr-Smith M, Lin J. Use of real-world claim databases to assess prevalence of comorbid conditions relevant to the treatment of chronic myelogenous leukemia based on National Comprehensive Network Treatment Guidelines. Clin Lymphoma Myeloma Leuk. 2015;15:797-802.

66.   Kamat SA, Offord S, Docherty J, Lin J, Eramo A, Baker RA, Gutierrez B, Karson C. Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. Drugs Context. 2015;4. pii: 212267.

67.   Ji L, Tsai ST, Lin J, Bhambani S. National variations in comorbidities, glycosylated hemoglobin reduction, and insulin dosage in Asian patients with type 2 diabetes: The FINE-Asia Registry. Diabetes Ther. 2015;6:2015

68.   Amin A, Lingohr-Smith M, Bruno A, Trocio J, Lin J. Economic evaluations of medical cost differences: Use of targeted-specific oral anticoagulants vs. warfarin among patients with nonvalvular atrial fibrillation and venous thromboembolism in the U.S. J Hematol Thrombo Dis. 2015;3:209.

69.   Joshi K, Lin J, Lingohr-Smith M, Fu DJ. Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder. J Med Econ. 2015;22:1-8.

70.   Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M. Incremental healthcare burden of bleeding among patients with venous thromboembolism in the U.S. J Manag Care Pharm. 2015;21:965-72.

71.   Amin A, Jing Y, Trocio J, Lin J, Lingohr-Smith M, Graham J. Evaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial results. J Thromb Thrombolysis. 2015;40:131-8.

72.   Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs. warfarin or placebo in the U.S. J Med Econ. 2015;18:399-409.

73.   Higgins P, Skup M, Mulani PM, Lin J, Chao J. Increased risk of venous thromboembolic events with corticosteroid versus biologic use in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13:316-21.

74.   Amin A, Jing Y, Trocio J, Lin J, Lingohr-Smith M, Graham J. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients. J Med Econ. 2014;17:763-70.

75.   Kim MH, Lin J, Jhaveri M, Koren A. Impact of dronedarone treatment on healthcare resource utilization in patients with atrial fibrillation/flutter. Adv Ther. 2014;31:318-32.

76.   Levin P, Wei W, Vlajnic A, Chunsen P, Xie L, Lin J, Baser O. Initiating injectable therapy in US managed care patients with diabetes. Am J Pharm Benefits. 2014;6:e93-e102.

77.   Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Estimation of the impact of warfarin’s time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. J Thromb Thrombolysis. 2014;38:150-9.

78.   Raccah D, Lin J, Wang E, Germé M, Perfetti R, Bonadonna RC, de Pablos-Velasco P, Roussel R, Rosenstock J. Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. J Diabetes Complications. 2014;28:40-4.

79.   Kim MH, Bell KF, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Healthcare burden of dyspepsia among nonvalvular atrial fibrillation patients. J Manag Care Pharm. 2014;20:391-9.

80.   Miao R, Wei W, Lin J, Xie L, Baser O. Does device make any difference? A real-world retrospective study of insulin treatment among elderly patients with type-2 diabetes. J Diabetes Sci Tech. 2014;8:150-8.

81.   Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Comparison of medical costs of atrial fibrillation patients unsuitable for warfarin treated with apixaban or aspirin, based on AVERROES trial. Clin Appl Thromb Hemost. 2013. Oct 9.

82.   Deitelzweig S, Amin  A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Medical costs of oral anticoagulants vs warfarin for atrial fibrillation patients with different stroke risks. Cardiol Therapy. 2013;2:165-70.

83.   Deitelzweig S, Amin  A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among nonvalvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials. J Med Econ. 2013;16:1163-8.

84.   Offord S, Lin J, Wong B, Mirski D, Baker RA. Impact of oral antipsychotic medication adherence on healthcare resource utilization among schizophrenia patients with Medicare coverage. Comm Ment Health J. 2013;49:625-9.

85.   Bera R, Offord S, Zubek D, Lau G, Lin J, Karson C. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy. J Clin Psychopharmacol. 2014;34:30-5.

86.   Lin J, Preblick R, Lingohr-Smith M, Kwong WJ. Incremental healthcare resource utilization and economic burden of venous thromboembolism recurrence from a US payer perspective. J Manag Care Pharm. 2014;20:174-86.

87.   Reynolds MR, Lin J, Jhaveri M, Mozaffari E, Plich A. Estimation of potential cost savings associated with reduced rates of cardiovascular hospitalization among atrial fibrillation/flutter patients treated with dronedarone in the ATHENA trial. Am J Ther. 2014;21:500-8.

88.   Lin J, Chow W, Kim MS, Rupnow MF. Real-world treatment pattern and outcomes among patients who took tapentadol IR or oxycodone IR. J Med Econ. 2013;16:685-90.

89.   Lin J, Wong B, Offord S, Mirski D. Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications vs. oral among patients with schizophrenia. J Behav Health Serv Res. 2013;40:355-66.

90.   Khorana AA, Dalal MR, Lin J, Connolly GC. Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clinicoecon Outcomes Res. 2013;5:101-8.

91.   Offord S, Lin J, Mirski D, Wong B. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther. 2013;30:286-97.

92.   Offord S, Wong B, Mirski D, Baker RA, Lin J. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs. oral. J Med Econ.  2013;16:231-9.

93.   Amin A, Lin J, Thompson S, Wiederkehr D. Rate of deep-vein thrombosis and pulmonary embolism during the care continuum in patients with acute ischemic stroke in the United States. BMC Neurology. 2013;13:17.

94.   Deitelzweig SD, Amin A, Christian R, Friend K, Lin J, Lowe TJ. Health care utilization, costs, and readmission rates associated with hyponatremia. Hospital Practice. 2013;41:89-95.

95.   Amin A, Deitelzweig S, Christian R, Friend K, Lin J, Lowe TJ. Healthcare resource burden associated with hyponatremia among patients hospitalized for heart failure in US. J Med Econ. 2013;16(3)415-20.

96.   Deitelzweig S, Amin A, Christian R, Friend K, Lin J, Lowe TJ. Hyponatremia-associated healthcare burden among US patients hospitalized for cirrhosis. Adv Ther. 2013;30(1):71-80.

97.   Connolly GC, Dalal M, Lin J, Khorana AA. Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. Lung Cancer. 2012;78(3):253-8.

98.   Amin A, Deitelzweig S, Christian R, Friend K, Lin J, Belk K, Baumer D, Lowe TJ. Evaluation of incremental healthcare resource burden and readmission rates associated with hospitalized hyponatremic patients in the US. J Hosp Med. 2012 Oct;7(8):634-9.

99.   Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013 Feb 1;119(3):648-55.

100. Dasta JF, Chiong JR, Christian R, Friend K, Lingohr-Smith M, Lin J, Cassidy IB. Update on tolvaptan for the treatment of hyponatremia. Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):399-410.

101. Pineo GF, Lin J, Annemans L. The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients. Clinicoecon Outcomes Res. 2012;4:99-107.

102. Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ. 2012;15(4):776-85.

103. Dasta JF, Chiong JR, Christian R, Lin J. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials. Hosp Pract (Minneap). 2012 Feb;40(1):7-14.

104. Amin AN, Jhaveri M, Lin J. Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors. Adv Ther. 2011 Oct;28(10):907-26.

105. Lepercq J, Lin J, Hall GC, Wang E, Dain MP, Riddle MC, Home PD. Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy. Obstet Gynecol Int. 2012;2012:649070.

106. Amin AN, Jhaveri M, Lin J. Temporal pattern and costs of rehospitalization in atrial fibrillation/atrial flutter patients with one or more additional risk factors. J Med Econ. 2012;15(3):548-55.

107. Guérin A, Lin J, Jhaveri M, Wu EQ, Yu AP, Cloutier M, Gauthier G, Alpert JS. Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy. Int J Cardiol. 2013;167:564-9.

108. Chiong JR, Kim S, Lin J, Christian R, Dasta JF. Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. J Med Econ. 2012;15(2):276-84.

109. Amin A, Varker H, Princic N, Lin J, Thompson S, Johnston S. Duration of Venous Thromboembolism Risk Across a Continuum in Medically-Ill Hospitalized Patients. J Hosp Med. 2012;7:231-8.

110. Kim MH, Smith PJ, Jhaveri M, Lin J, Klingman D. One Year Treatment Persistence and Potential Adverse Events Among Patients with Atrial Fibrillation Treated With Amiodarone or Sotalol: A Retrospective Claims Database Analysis. Clin Ther. 2011 Nov;33(11):1668-1681.

111. Naccarelli GV, Johnson SS, Dalal M., Lin J, Patel PP. Rates and Implications for Hospitalization of Patients ≥65 Years of Age with Atrial Fibrillation/Flutter. Am J Cardiol. 2011 Nov 23.

112. Amin AN, Jhaveri M and Lin J. Incremental Cost Burden to US Payers of Atrial Fibrillation/Atrial Flutter Patients with Additional Risk Factors. Adv Ther. 2011 Oct;28(10):907-26.

113. Joish VN, Boklage S, Lynen R, Schmidt A, Lin J. Use of drospirenone/ethinyl estradiol (DRSP/EE) among women with acne reduces acne treatment–related resources. J Med Econ. 2011;14(6):681-9.

114. Pineo G, Lin J, Stern L, Subrahmanian T, Annemans L. The Economic Impact of Enoxaparin Versus Unfractionated Heparin for Venous Thromboembolism Prophylaxis in Patients with Acute Ischemic Stroke: A Hospital Perspective of the PREVAIL Trial. J Hosp Med. 2012 Mar;7(3):176-82.

115. Amin AN, Lin J, Thompson S, Wiederkehr D. Real-World Rates of Inhospital and Post-Discharge Deep-Vein Thrombosis and Pulmonary Embolism in At-Risk Medical Patients in the US. Clin Appl Thromb Hemost. 2011 Nov-Dec;17(6):611-9.

116. Amin AN, Lin J, Thompson S, Wiederkehr D. Inpatient and Outpatient Occurrence of Deep-Vein Thrombosis and Pulmonary Embolism and Thromboprophylaxis in US Patients Following Selected At-Risk Surgeries. Ann Pharmacother. 2011 Sep;45(9):1045-52.

117. Deitelzweig SB, Lin J and Lin G. Preventing venous thromboembolism following orthopedic surgery in the United States: impact of special populations on clinical outcomes. Clin Appl Thromb Hemost. 2011 Nov-Dec;17(6):640-50.

118. Merli GJ, Malangone E, Lin J, Lamerato L, Stern L. Real-world practices to prevent venous thromboembolism with pharmacological prophylaxis in US orthopedic surgery patients: An analysis of an integrated healthcare database.  J Thromb Thrombolysis. 2011 Jul;32(1):89-95.

119. Amin A, Lenhart G, Princic N, Lin J, Thompson S, Johnston S. Retrospective Administrative Database Study of the Time Period of Venous Thromboembolism Risk During and Following Hospitalization for Major Orthopedic or Abdominal Surgery in Real-World US Patients. Hosp Pract (Minneap). 2011 Apr;39(2):7-17.

120. Deitelzweig SB, Johnson BH, Lin J, Schulman KL. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol. 2011 Feb;86(2):217-20.

121. Deitelzweig SB, Johnson BH, Lin J, and Schulman KL. Venous thromboembolism in the US: does race matter? J. Thromb Thrombolysis. 2011 Feb; 31(2):133-8.

122. Pineo G, Lin J, Stern L, Subrahmanian T, Annemans L. Economic Impact of Enoxaparin after Acute Ischemic Stroke Based on PREVAIL. Clin Appl Thromb Hemost. 2011 Apr;17(2):150-7.

123. Deitelzweig S, Lin J, Kreilick C, Hussein M, Battleman D. Warfarin Therapy in Patients with Venous Thromboembolism: Patterns of Use and Predictors of Clinical Outcomes. Adv Ther. 2010 Sep;27(9):623-33. Epub 2010 Jul 30.

124. Kim MH, Lin J, Foltz Boklage SH, Kreilick CA. Total costs and atrial fibrillation ablation success or failure in Medicare-aged patients in the US. Adv Ther. 2010 Sep;27(9):600-12. Epub 2010 Aug 9.

125. Deitelzweig S, Lin J, Hussein M, Battleman D. Are surgical patients at risk of venous thromboembolism currently meeting the Surgical Care Improvement Project performance measure for appropriate and timely prophylaxis? J Thromb Thrombolysis. 2010 Jul;30(1):55-66.

126. Naccarelli GV, Johnson SS, Lin J, Patel PP, Schulman KL. Cost Burden of Cardiovascular Hospitalization and Mortality in ATHENA-Like Patients with Atrial Fibrillation/Atrial Flutter in the United States. Clin Cardiol. 2010 May;33(5):270-9

127. Amin, AN, Lin J, Johnson BH and Schulman KL. Clinical and economic outcomes with appropriate or partial prophylaxis. Thromb Res. 2010 Jun;125(6):513-517.

128. Amin AN, Lin J and Ryan A. Lack of Thromboprophylaxis Across the Care Continuum in US Medical Patients. Hosp Pract (Minneap). 2010 Jun;38(3):17-25.

129. Zimetbaum, PJ, Thosani A, Yu H, Xiong Y, Lin J, Kothawala P, Emons M. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Amer J Med. 2010 May;123(5):446-53.

130. Merli G, Ferrufino CP, Lin J, Hussein M, Battleman D. Hospital-based Costs Associated with Venous Thromboembolism Prophylaxis Regimens.  J Thromb Thrombolysis. 2010 May;29(4):449-58.

131. Amin AN, Lin J, Ryan A. Need to Improve Thromboprophylaxis Across the Continuum of Care for Surgical Patients. Adv Ther. 2010 Feb;27(2):81-93.

132. Kim MH, Lin J, Hussein M, Kreilick C and Battleman DS. Cost of atrial fibrillation in United States managed care organizations. Adv Ther. 2009 Sep;26(9):847-57

133. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing Prevalence Of Atrial Fibrillation And Flutter In The United States. Amer J Cardiol. 2009 Dec 1;104(11):1534-9.

134. Kim MH, Klingman D, Lin J, Battleman DS.  Patterns and Predictors of Discontinuation of Rhythm-Control Therapy in Patients with Newly-Diagnosed Atrial Fibrillation.  Pharmacother. 2009 Dec;29(12):1417-26.

135. Kim MH, Lin J, Hussein M and Battleman D. Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy. Curr Med Res Opin. 2009 Dec;25(12):3037-47.

136. Ishak J., Proskorovsky I., Guo S., Lin J., Caro J. Persistence with anti-arrhythmics and its impact on atrial fibrillation-related outcomes. Amer J Pharm Benefits. 2009;1(4):193-200.

137. Kim MH, Lin J and Kreilick C. National Assessment of Medicare Prescription-Plan Coverage Gaps Among Atrial Fibrillation Patients in the United States. Adv Ther. 2009 Aug;26(8):784-94.

138. Spyropoulos AC, Hussein M, Lin J, Battleman D. Rates of symptomatic venous thromboembolism in US surgical patients: a retrospective administrative database study. J Thromb Thrombolysis. 2009 Nov;28(4):458-64.

139. Spyropoulos AC, Hussein M, Lin J, Battleman D. Rates of venous thromboembolism occurrence in medical patients among the insured population. Thromb Haemost. 2009 Nov;102(5):951-7.

140. Amin AN, Lin J, Lenhart G, Schulman KL. Clinical and economic outcomes in patients at risk for venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis. Thromb Haemost. 2009 Aug;102(2):321-6.

141. Amin AN, Stemkowski S, Lin J, Yang G. Thromboprophylaxis use in US Hospitals: Adherence to the Seventh American College of Chest Physician’s Recommendations for At-Risk Medical and Surgical Patients. J Hosp Med. 2009 Oct;4(8):E15-21

142. Amin AN, Lin J, Yang G, Stemkowski S. Are there any differences in the clinical and economic outcomes between US cancer patients receiving appropriate or inappropriate VTE prophylaxis? J Oncol Pract. Vol 5, No 4 (July), 2009: 159-164.

143. Kim MH, Lin J, Hussein M, Battleman, D. Incidence and temporal pattern of hospital readmissions for patients with atrial fibrillation. Curr Med Res Opin, May 2009, Vol. 25, No. 5, 1215-1220. Accompanied by an Editorial Commentary: Burden of atrial fibrillation. Chee W. Khoo and, Gregory Y. H. Lip Current Medical Research and Opinion, May 2009, Vol. 25, No. 5, 1261-1263

144. Kim M, Klingman D, Lin J, Pathak P, Battleman D. Cost of Hospital Admission for Antiarrhythmic Drug Initiation in Atrial Fibrillation in the United States, Ann Pharmacother. 2009 May; 43(5):840-8.

145. Amin A, Stemkowski S, Lin J, Yang G. Appropriate thromboprophylaxis in hospitalized cancer patients. Clin Adv Hemat Oncol, Vol. 6, Issue 12, Dec 2008: 910-920.

146. Baroletti S, Piovella C, Fanikos J, Labreche M, Lin J, Goldhaber SZ. Heparin-induced thrombocytopenia (HIT): Clinical and economic outcomes. Thromb Haemost. 2008, 100 6: 1130-1135.

147. Deitelzweig S, Becker R, Lin J, Benner J.  Comparison of the 2-year clinical and economic outcomes of VTE prophylaxis options in medical patients at risk of VTE. Thromb Haemost. 2008 100 5: 810-820.

148. Merli G, Ferrufino C, Lin J, Hussein M, Battleman, D. Hospital-based costs associated with VTE treatment regimens. J Thromb Haemost. 2008 Jul; 6(7):1077-86.

149. Amin A, Stemkowski S, Lin J, Yang G. Preventing venous thromboembolism in US hospitals: are surgical patients receiving appropriate prophylaxis? Thromb Haemost. Apr 2008; 99(4):796-7.  

150. Spyropoulos AC, Lin J.  Direct Medical Costs of Venous Thromboembolism and Subsequent Hospital Readmission Rates: An Administrative Claims -- Analysis From 30 Managed Care Organizations. J Manag Care Pharm. Aug. 2007, Vol 13, Issue 6, 475-486.

151. Amin A, Stemkowski S, Lin J, Yang G. Thromboprophylaxis rates in US medical centers: success or failure? J Thromb Haemost, Aug. 2007 - Vol. 5 Issue 8, 1610–1616.Accompanied by an editorial comment: Goldhaber SZ. Preventing pulmonary embolism and deep vein thrombosis: a 'call to action' for vascular medicine specialists. J Thromb Haemost. 2007 Aug;5(8):1607-9.

152. Yu HT, Dylan ML, Lin J, Dubois RW. Hospitals' compliance with prophylaxis guidelines for venous thromboembolism. Amer J Health Syst Pharm. 2007 Jan 1;64(1):69-76.

153. MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Amer J Health Syst Pharm. 2006; Volume 63.

ABSTRACTS AND CONFERENCE PRESENTATIONS

1.      Watkins E, Lin J, Lingohr-Smith M, Yong C, Tangirala K, Collins K. Factors associated with disproportionate burden of bacterial vaginosis in the United States. Royal College of Obstetricians and Gynaecologists (RCOG) World Congress, London, UK, June 12-14, 2023. Poster.

2.  Ghosh T, Lin J, Namjoshi M, Witte M, Potter M, Lingohr-Smith M, Gannu L, Hass S, Tarazi F. Total cost of care following first-line antidepressant treatment failure among patients with major depressive disorder in the United States. Psych Congress Elevate, Las Vegas, NV, June 1-4, 2023. Poster.

3.      Watkins E, Lin J, Lingohr-Smith M, Yong C, Tangirala K, Collins K. Economic burden of bacterial vaginosis in the United States: a systematic literature review. Academy of Managed Care Pharmacy (AMCP) Annual Meeting, San Antonio, TX, March 21-24, 2023. Poster.

4.      Ghosh T, Lin J, Suthoff E, Namjoshi M, Witte M, Lingohr-Smith M, Potter M, Hass S. Total cost of care during a 90-day period post antidepressant treatment initiation following a recent insurance coverage gap among US employees with major depressive disorder. Academy of Managed Care Pharmacy (AMCP) Annual Meeting, San Antonio, TX, March 21-24, 2023. Poster.

5.      Smith T, Nguyen A, Henderson C, Beaubrun A, Lingohr-Smith M, Lin J, Campbell A. Prevalence of complication among adult and pediatric Medicaid-insured patients with sickle cell disease in the United States. Academy of Managed Care Pharmacy (AMCP) Nexus, National Harbor, MD, October 11-14, 2022. Poster.

6.      Campbell A, Nguyen A, Henderson C, Beaubrun A, Lingohr-Smith M, Lin J, Smith T. Mental health-related burden among patients with sickle cell disease with Medicaid coverage. Academy of Managed Care Pharmacy (AMCP) Nexus, National Harbor, MD, October 11-14, 2022. Poster.

7.      Lin G, Lingohr-Smith M, Deitelzweig C, Lin J. Efficacy of PD1/PD-L1 inhibitors vs chemotherapy as first-line treatment of non-small cell lung cancer among patients with different PD-L1 expression levels. ISPOR: International Society for Pharmacoeconomics and Outcomes Research Annual Meeting (Virtual and In-person), Washington DC, May 15-18, 2022. Virtual Poster.

8.      Lingohr-Smith M, Deitelzweig C, Lin G, Lin J. Efficacy of FDA-approved Disease-modifying Therapies (DMTs) versus Active Comparator Medications for Relapsing-remitting Multiple Sclerosis: A Systematic Review. ISPOR: International Society for Pharmacoeconomics and Outcomes Research Annual Meeting (Virtual and In-person), Washington DC, May 15-18, 2022. Virtual Poster.

9.      Gish RG, Wheeler D, Lin J, Adekunle F, Lingohr Smith M, Bassanelli C, Law A. Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis Stratified by Biochemical Marker Status in the Real-World Setting in the United States. ILC: The International Liver Congress (Virtual Meeting), June 23-26, 2021. Poster.

10.   McComsey GA, Donga P, Lingohr-Smith M, Rogers R, Lin J. Adherence to Antiretroviral Therapy Among HIV-1 Patients Across Regions in the United States. ACTHIV: American Conference for the Treatment of HIV (Virtual Meeting), May 20-22, 2021. Poster

11.   Seal B, Aly A, Healy M, Lingohr-Smith M, Lin J. A Retrospective Observational Analysis of the Healthcare Economic Burden of Patients Newly Diagnosed with Hepatocellular Carcinoma and Treated with Locoregional Therapies in the United States. ISPOR: International Society for Pharmacoeconomics and Outcomes Research (Virtual Meeting), May 17-20, 2021. Poster.

12.   Zhang Q, O’Hara M, McCormick C, Lingohr-Smith M, Borentain S, Mathews M, Lin J. Patient Profiles and Hospital Re-encounters of Patients with a Hospital Emergency Department Visit or Inpatient Admission for Major Depressive Disorder. ISPOR: International Society for Pharmacoeconomics and Outcomes Research (Virtual Meeting), May 17-20, 2021. Poster.

13.   Lingohr-Smith M, Deitelzweig C, Lin G, Lin J. Efficacy and Safety of Disease-modifying Therapies for the Treatment of Relapsing-remitting Multiple Sclerosis: A Systematic Review. ISPOR: International Society for Pharmacoeconomics and Outcomes Research (Virtual Meeting), May 17-20, 2021. Poster.

14.   Lingohr-Smith M, Deitelzweig C, Lin G, Lin J. Disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a comparison of their efficacy for reducing relapse rate. ACTRIMS: Americas Committee for Treatment and Research in Multiple Sclerosis Forum (Virtual Meeting), February 25-27, 2021. Poster.

15.   Seal B, Aly A, Lingohr-Smith M, Lin J. The Lines of Loco-regional Therapies Received and the Healthcare Economic Burden of Patients Newly Diagnosed with Hepatocellular Carcinoma in the United States. ASCO Gastrointestinal Cancers Symposium (Virtual Meeting), January 15-17, 2021. Poster.

16.   Lingohr-Smith M, Deitelzweig C, Lin G, Lin J. Systematic Review of Efficacy of Programmed Death (PD)-1 and PD-Ligand-1 Inhibitors in the Treatment of Non-small Cell Lung Cancer. ISPOR-EU: International Society for Pharmacoeconomics and Outcomes Research-Europe (Virtual Meeting), November 14-18, 2020. Poster.

17.   Deitelzweig S, Dhamane AD, Di Fusco M, Russ C, Rosenblatt L, Lingohr-Smith M, Lin J. Predictors of Treatment of Hospitalized Patients with Atrial Fibrillation in the US. AHA: American Heart Association Scientific Sessions (Virtual Meeting), November 13-17, 2020. Poster.

18.   Deitelzweig SB, Lovelace B, Christoph M, Lingohr-Smith M, Lin J, Fermann GJ. Healthcare Costs of Atrial Fibrillation Patients Treated with Factor Xa Inhibitors who have a Hospitalization with a Major Bleed in the United States. AHA: American Heart Association Scientific Sessions (Virtual Meeting), November 13-17, 2020. Oral Audio Presentation.

19.   Mozaffari E, Law A, Lingohr-Smith M, Randhawa A, Velez de Villa B, Lin J. Economic Burden of NASH-associated Cirrhosis: US Payor’s Perspective. AASLD: American Association for the Study of Liver Diseases (Virtual Meeting), November 13-16, 2020. Poster.

20.   Gish RG, Law A, Lingohr-Smith M, Adekunle F, Wheeler D, Velez de Villa B, Bassanelli C, Lin J. Primary Biliary Cholangitis: Patient Characteristics and the Healthcare Economic Burden in the United States. AASLD: American Association for the Study of Liver Diseases (Virtual Meeting), November 13-16, 2020. Poster.

21.   Gish RG, Law A, Adekunle F, Wheeler D, Lingohr-Smith M, Bassanelli C, Velez de Villa B, Lin J. Real-world Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis. AASLD: American Association for the Study of Liver Diseases (Virtual Meeting), November 13-16, 2020. Poster.

22.   Lingohr-Smith M, Deitelzweig C, Lin G, Lin J. Programmed Death (PD)-1 and PD-ligand-1 Inhibitors in the Treatment of Non-small Cell Lung Cancer: A Systematic Review of their Efficacy and Safety. SITC: Annual Meeting of the Society for Immunotherapy of Cancer (Virtual Meeting), November 12-15, 2020. Poster.

23.   Fermann GJ, Lovelace B, Christoph MJ, Lingohr-Smith M, Lin J, Deitelzweig SB. Incremental Healthcare Economic Burden of Atrial Fibrillation Patients Treated with Factor Xa Inhibitors and Hospitalized with a Major Bleed. ACEP: American College of Emergency Physicians Research Forum (Virtual Meeting). October 26-29, 2020. Poster.

24.   Liao L, Lott JP, Kong S, Fu C, Lin J, Bansilal S. Comparison of Healthcare Costs of Pulmonary Arterial Hypertension Patients with Phosphodiesterase 5 Inhibitor Failure who Switched to Riociguat vs. Those who Augmented Therapy. ACCP: The American College of Chest Physicians Annual Meeting (Virtual Meeting), October 18-21, 2020. Poster.

25.   Aly A, Lingohr-Smith M, Lin J, Seal B. Comorbidities and Economic Burden of Patients Diagnosed with Hepatocellular Carcinoma Treated with Systemic Therapy in the United States. AMCP: Academy of Managed Care Pharmacy Nexus Meeting (Virtual Meeting), October 16-23, 2020. Poster.

26.   Deitelzweig SB, Lovelace B, Christoph MJ, Lingohr-Smith M, Lin J, Fermann GJ. Healthcare Economic Burden of Atrial Fibrillation Patients Treated with Oral Factor Xa Inhibitors who were Hospitalized for Intracranial Hemorrhage. NCS: Neurocritical Care Society Annual Meeting (Virtual Meeting), September 23-25, 2020. Poster.

27.   Fermann GJ, Lovelace B, Christoph MJ, Lingohr-Smith M, Lin J, Deitelzweig SB. Healthcare Economic Burden in the United States of Atrial Fibrillation Patients Treated with Oral Factor Xa Inhibitors and Hospitalized with a Major Bleed. The European Emergency Medicine Congress (Virtual Meeting), September 19-22, 2020. Poster.

28.   Neslusan C Voelker J, Lingohr-Smith M, Lin J. Hospital Encounters of Patients with Concurrent Major Depressive Disorder (MDD) and Suicidal Ideation or Suicide Attempt: Characteristics and Potential Predictors of a Subsequent MDD-related Hospital Encounter. American College of Clinical Pharmacy Virtual Poster Symposium, May 26-27, 2020. Encore Poster.

29.   Neslusan C Voelker J, Lingohr-Smith M, Lin J. Hospital Encounters of Patients with Concurrent Major Depressive Disorder (MDD) and Suicidal Ideation or Suicide Attempt: Characteristics and Potential Predictors of a Subsequent MDD-related Hospital Encounter. American Society of Clinical Psychopharmacology Virtual Conference, May 29-30, 2020. Poster.

30.   Deitelzweig S, Dhamane AD, Di Fusco M, Russ C, Rosenblatt L, Mardekian J, Lingohr-Smith M, Lin J. Examination of Anticoagulant Treatment Patterns of Patients with Nonvalvular Atrial Fibrillation During a Hospital Stay in the US. American College of Cardiology, Chicago, IL, March 28-30, 2020 (Conference cancelled, virtual poster).

31.   Fermann GJ, Lovelace B, Christoph M, Lingohr-Smith M, Lin J, Deitelzweig SB. Healthcare Economic Burden Associated with Major Bleeding Among Atrial Fibrillation Patients Treated with Factor Xa Inhibitors in the U.S. Emergencies in Medicine Annual Conference, Park City, UT, March 1-6, 2020. Poster.

32.   Deitelzweig S, Hlavacek P, Mardekian J, Rosenblatt L, Russ C, Tuell K, Lingohr-Smith M, Lin J, Guo JD. Differences in admission rates among patients treated with apixaban vs. warfarin for venous thromboembolism in the emergency department. American Society of Hematology 61st Annual Meeting and Exposition, Orlando, FL, December 7-10, 2019. Poster.

33.   Feldman SR, Jacobson AA, Lin J. Effect of Prior Biologic Use on the Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States. 19th Las Vegas Dermatology Seminar, Las Vegas, NV, November 7-9, 2019. Poster.

34.   Amin A, Bucior I, Lingohr-Smith M, Menges B, Lin J, Deitelzweig S. Burden of Hospital Readmissions for Venous Thromboembolism Among Patients Hospitalized for Non-Cancer Acute Medical Illness in the US. Congress of the International Society on Thrombosis and Haemostasis and Annual Scientific and Standardization Committee Meeting, Melbourne, Australia, July 6-10, 2019. Poster.

35.   Neslusan C, Amos T, Szukis H, Chow W, Lingohr-Smith M, Lin J, Daly E, Sheehan JJ. Length of Stay and Readmission/Subsequent ED Visit Risk Among Patients with Major Depressive Disorder and Suicide Ideation or Suicide Attempt. American Psychiatric Association Annual Meeting, San Francisco, CA, May 18-22, 2019. Poster.

36.   Neslusan C, Amos T, Szukis H, Chow W, Lingohr-Smith M, Lin J, Daly E, Sheehan JJ. Care Setting Type and Readmission/Subsequent ED Visit Risk Among Patients with Major Depressive Disorder and Suicide Ideation or Suicide Attempt. American Psychiatric Association Annual Meeting, San Francisco, CA, May 18-22, 2019. Poster.

37.   Baker CL, Dhamane AD, Rajpura J, Mardekian J, Dina O, Russ C, Rosenblatt L, Lingohr-Smith M, Lin J. Switching vs. Continuing Apixaban Treatment is Associated with a Greater Risk for Major Bleeding-related Hospitalization in Elderly Patients with NVAF. International Society for Pharmacoeconomics and Outcomes Research Annual Meeting, New Orleans, LA, May 18-22, 2019. Poster.

38.   Mandras S, Liao L, Lin W, Bansilal S, Lin J. Healthcare Resource Utilization, Cost, and Treatment Persistence among Treatment-Naïve PAH Patients Initiating Monotherapy vs. Combination Therapy. International Society for Pharmacoeconomics and Outcomes Research Annual Meeting, New Orleans, LA, May 18-22, 2019. Poster.

39.   Mandras S, Liao L, Lin W, Bansilal S, Lin J. Evaluation of the Real-World Incremental Cost Burden of Newly Treated PAH in the US. International Society for Pharmacoeconomics and Outcomes Research Annual Meeting, New Orleans, LA, May 18-22, 2019. Poster.

40.   Deitelzweig S, Amin A, Bucior I, Lin J, Lingohr-Smith M, Menges B. The Burden of Hospital Readmissions for Venous Thromboembolism Among Acute Medically Ill Patients in the US. Anticoagulation Forum, Fort Lauderdale, FL, April 11-13, 2019. Poster.

41.   Baker CL, Dhamane AD, Rajpura J, Mardekian J, Dina O, Russ C, Rosenblatt L, Lingohr-Smith M, Lin J. Rates of Drug Switching and Discontinuation among Nonvalvular Atrial Fibrillation Elderly Patients Treated with Direct Oral Anticoagulants in the US. American Heart Association Quality of Care and Outcomes Research Scientific Sessions, Arlington, VA, April 5-6, 2019. Poster.

42.   Deitelzweig S, Lin J, Lingohr-Smith M, Menges B, Bucior I, Amin A. Frequency and Costs of Rehospitalizations for Venous Thromboembolism Among Patients with Infectious Diseases. Society of Hospital Medicine Annual Conference, National Harbor, MD, March 24-27, 2019. Poster.

43.   Neslusan C, Amos T, Szukis H, Chow W, Lingohr-Smith M, Lin J, Daly E, Sheehan JJ. What are the Rates and Costs of Readmissions and Subsequent Emergency Visits Among Hospitalized Patients with Major Depressive disorder and Suicidal Ideation or Suicide Attempt? Society of Hospital Medicine Annual Conference, National Harbor, MD, March 24-27, 2019. Poster.

44.   Neslusan C, Amos T, Szukis H, Chow W, Lingohr-Smith M, Lin J, Daly E, Sheehan JJ. Economic Burden of Patients with Major Depressive Disorder Patients and Suicidal Ideation or Suicide Attempt: A Retrospective Hospital-Based Database Analysis. Society of Hospital Medicine Annual Conference, National Harbor, MD, March 24-27, 2019. Poster.

45.   Deitelzweig S, Baker CL, Dhamane AD, Mardekian J, Dina O, Poretta T, Lingohr-Smith M, Lin J. Comparison of Major Bleeding- and Stroke-related Hospital Readmissions Among Hospitalized Nonvalvular Atrial Fibrillation Patients Treated with Warfarin and Apixaban in the US. American College of Cardiology Annual Meeting. New Orleans, LA, March 16-18, 2019. Poster.

46.   Amin A, Deitelzweig S, Lin J, Lingohr-Smith M, Menges B, Neuman WR. Burden of Rehospitalizations for Venous Thromboembolism Among Patients with Ischemic Stroke. International Stroke Conference, Honolulu, HI, February 6-8, 2019. Poster.

47.   Feldman SR, Wu JJ, Armstrong AW, Lebwohl M, Jacobson AA, Lingohr-Smith M, Lin J. Evaluating Costs of Biologic Drugs for the Treatment of Moderate-to-Severe Psoriasis in the United States. Winter Clinical Dermatology Conference, Koloa, HI, January 18-23, 2019. Poster.

48.   Amin A, Deitelzweig S, Lin J, Lingohr-Smith M, Menges B, Neuman WR. Burden of Hospital Readmissions for Venous Thromboembolism Among Patients with Cancer. American Society of Hematology Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018. Poster.

49.   Jabbour EJ, Mendiola MF, Lingohr-Smith M, Menges B, Lin J, Makenbaeva D. The Impact of Chronic Myeloid Leukemia Therapy Management on the Oncology Care Model. American Society of Hematology Annual Meeting & Exposition, San Diego, CA, December 1-4, 2018. Poster.

50.   Baker CL, Dhamane AD, Mardekian J, Dina O, Russ C, Rosenblatt L, Lingohr-Smith M, Menges B, Lin J, Nadkarni A. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Different Direct Oral Anticoagulants in the US. American Heart Association Scientific Sessions, Chicago, IL, November 10-12, 2018. Poster.

51.   Deitelzweig S, Guo JD, Hlavacek P, Lin J, Wygant G, Rosenblatt L, Gupta A, Pan X, Mardekian J, Lingohr-Smith M, Menges B, Marshall A, Nadkarni A. Comparison of 1-Month Readmissions of Patients Hospitalized for Venous Thromboembolism and Treated with Warfarin vs. Apixaban in the US. American Heart Association Scientific Sessions, Chicago, IL, November 10-12, 2018. Poster.

52.   Baker CL, Dhamane AD, Mardekian J, Dina O, Russ C, Rosenblatt L, Lingohr-Smith M, Menges B, Lin J, Nadkarni A. Patients with Nonvalvular Atrial Fibrillation who Continue Apixaban Treatment Have Lower Healthcare Costs Compared with Patients who Switch to Another Oral Anticoagulant. Academy of Managed Care Pharmacy (AMCP) Nexus Meeting, Orlando, FL, October 22-25, 2018. Poster.

53.   Gupta K, Marshall A, Ferri L, Menges B, Lingohr-Smith M, Lin J. Impact of Treatment with Other Targeted Disease Modifying Antirheumatic Drugs vs. Abatacept on Type 2 Diabetes-related Healthcare Costs Among Tumor Necrosis Factor-α Inhibitor Experienced Rheumatoid Arthritis Patients. Academy of Managed Care Pharmacy (AMCP) Nexus Meeting, Orlando, FL, October 22-25, 2018. Poster.

54.   Amin A, Deitelzweig S, Bucior I, Lin J, Lingohr-Smith M, Menges B, Neuman WR. Frequency of Hospital Readmissions for Venous Thromboembolism and Associated Hospital Costs Among Acute Medically Ill Patients in the US. Academy of Managed Care Pharmacy (AMCP) Nexus Meeting, Orlando, FL, October 22-25, 2018. Poster.

55.   Paul D, McDonald L, Marshall A, Curtice T, Lingohr-Smith M, Menges B, Lin J. Comparison of Risk for Infection-related Hospitalization and Associated Costs of Biologic Experienced Rheumatoid Arthritis Patients Treated with Abatacept versus Other Targeted Disease Modifying Antirheumatic Drugs. American College of Rheumatology Annual Meeting, Chicago, IL, October 16-24, 2018. Poster.

56.   Lin J, Choi J, Curtis JR, Lingohr-Smith M, Boklage S. Identifying Trends in Lines of Therapy Following Initial Biologic Disease-Modifying Antirheumatic Drug in Patients with Rheumatoid Arthritis. American College of Rheumatology Annual Meeting, Chicago, IL, October 16-24, 2018. Oral Presentation.

57.   Paul D, McDonald L, Marshall A, Curtice T, Lingohr-Smith M, Menges B, Lin J. The Impact of Second-Line Therapy with Abatacept versus Other Targeted Disease Modifying Antirheumatic Drugs on the Risk for Infection-Related Hospitalizations and Associated Costs Among Rheumatoid Arthritis Patients in the United States. Annual European Congress of Rheumatology, Amsterdam, Netherlands, June 13-16, 2018, Poster.

58.   Filonenko A, Law A, Yao J, Lin J. The Economic Burden of Mechanically Ventilated Patients with Pneumonia in the US. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual International Meeting, Baltimore, MD, May 19-23, 2018, Poster.

59.   Wu JJ, Feldman SR, Rastogi S, Menges B, Lingohr-Smith M, Lin J. A Cost-Effectiveness Analysis of Commonly Used Biologic Drugs for the Treatment of Moderate-to-Severe Psoriasis in the United States. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual International Meeting, Baltimore, MD, May 19-23, 2018, Poster

60.   Feldman SR, Wu JJ, Rastogi S, Menges B, Lingohr-Smith M, Lin J. The Budget Impact of Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis on U.S. Commercial Health Plans. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual International Meeting, Baltimore, MD, May 19-23, 2018, Poster.

61.   Menges B, Deitelzweig C, Lingohr-Smith M, Lin G. Systematic Review of Poly(ADP-ribose) polymerase Inhibitors for Treatment of Ovarian Cancer. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual International Meeting, Baltimore, MD, May 19-23, 2018, Poster.

62.   Amin A, Neuman WR, Lingohr-Smith M, Menges B, Lin J. Real-World Evaluation of Hospital Length of Stay and Cost For Apixaban Versus Warfarin Treatment of Hospitalized Venous Thromboembolism Patients in the US. American College of Cardiology's 67th Annual Scientific Session, Orlando, FL, March 10-12, 2018. Moderated Poster.

63.   Amin A, Neuman WR, Lingohr-Smith M, Menges B, Lin J. The Risk of Venous Thromboembolism Among Patients Hospitalized for Acute Ischemic Stroke in the US. International Stroke Conference, Los Angeles, CA, January 24-26, 2018. Poster.

64.   Amin A, Neuman WR, Lingohr-Smith M, Menges B, Lin J. The Frequency of Venous Thromboembolism (VTE) Prophylaxis Among Patients Hospitalized for Cancer in the US. American Society of Hematology 59th Annual Meeting and Exposition, Atlanta, GA, December 9-12, 2017. Poster.

65.   Amin A, Neuman WR, Lingohr-Smith M, Menges B, Lin J. Did Patients with Renal Disease Receive Sufficient Prophylaxis for Venous Thromboembolism in the Real-World Settings?: A Study Among Hospitalized Acutely Medically Ill Patients. American Society of Hematology 59th Annual Meeting and Exposition, Atlanta, GA, December 9-12, 2017. Poster.

66.   Amin A, Neuman WR, Lingohr-Smith M, Menges B, Lin J. Frequency and characterization of venous thromboembolism prophylaxis in the inpatient and outpatient continuum of care among at-risk hospitalized patients in the US. ASHP Midyear Meeting, Orlando, FL, December 3-7, 2017. Poster.

67.   Amin A, Lee J, Neuman WR, Lingohr-Smith M, Menges B, Lin J. Venous Thromboembolism Events and Prophylaxis in the Inpatient and Outpatient Continuum of Care Among Acutely Ill Medical Patients in the United States. Encore poster presentation. AMCP Nexus, Dallas, TX, October 16-19, 2017. Poster.

68.   Amin A, Lee J, Neuman WR, Lingohr-Smith M, Menges B, Lin J. Venous thromboembolism prophylaxis and risk in the inpatient and outpatient continuum of care among acutely ill medical patients in the US. 2017 ACCP Annual Meeting, Phoenix, AZ, October 7-10, 2017. Poster.

69.   Liu, Y, Lin J, Shah A, Lingohr-Smith M Menges G, Gore M. Elevated Healthcare Resource Utilization and Costs among Patients with a Dual Diagnosis of Schizophrenia and Alcohol Use Disorder. Society for Medical Decision Making North American Meeting, Pittsburgh, PA, October 22-25, 2017. Poster.

70.   Amin A, Neuman WR, Lingohr-Smith M, Menges B, Lin J. The Risk of Venous Thromboembolism and Prophylaxis in the Inpatient and Outpatient Continuum of Care Among Acutely Ill Medical Patients in the United States. 15th Annual Neurocritical Care Society Meeting, Waikoloa Village, HI, October 11-13, 2017. Poster

71.   Deitelzweig S, Luo X, Gupta K, Trocio J, Mardeckian J, Curtice T, Lingohr-Smith M, Menges B, Lin J. Comparison of Stroke and Major Bleeding Risk of Treatment with Apixaban vs. Rivaroxaban and Dabigatran Among Elderly Nonvalvular Atrial Fibrillation (NVAF) Patients in the United States. ESC Congress, Barcelona, Spain, August 26-30, 2017. Oral Presentation.

72.   Gupte-Singh K, Lin J, Lingohr-Smith M, Menges B, Rao S. Adherence to Cancer Therapies and the Impact on Healthcare Costs Among Patients with Advanced Melanoma in the US. ISPOR 22nd Annual International Meeting, Boston, MA, May 20-24, 2017. Poster.

73.   Deitelzweig S, Luo X, Gupta K, Trocio J, Mardeckian J, Curtice T, Lingohr-Smith M, Menges B, Lin J. Evaluation of Healthcare Costs of Elderly Nonvalvular AtriaL Fibrillation Patients Treated with Apixaban vs. Rivaroxaban or Dabigatran. ISPOR 22nd Annual International Meeting, Boston, MA, May 20-24, 2017. Poster.

74.   Lingohr-Smith M, Deitelzweig C, Menges B, Lin G. Costs of breast cancer related care among women in the United States insured commercially, and by Medicare and Medicaid - a systematic review. ISPOR 22nd Annual International Meeting, Boston, MA, May 20-24, 2017. Poster.

75.   Yong C, Seal B, Lingohr-Smith M, Menges S, Noga SJ, Lin J. Healthcare burden among patients newly diagnosed with multiple myeloma with commercial and Medicare insurance coverage in the US. ISPOR 22nd Annual International Meeting, Boston, MA, May 20-24, 2017. Poster.

76.   Yong C, Seal B, Lingohr-Smith M, Menges S, Noga SJ, Lin J. First-line treatment patterns among younger versus older patients newly diagnosed with multiple myeloma in the US. ISPOR 22nd Annual International Meeting, Boston, MA, May 20-24, 2017. Oral presentation.

77.   Carney PI, Yao J, Lin J, Law A. Occurrence of abnormal uterine bleeding post-procedure among women who have undergone female sterilization procedures: a retrospective claims analysis of commercially insured women in the US. Women's Health 2017: 25th Annual Congress, Washington DC, April 28-30, 2017. Poster.

78.   Law A, Lynen R, Liao L, Lin J, Yaldo A. Discontinuation rates of levonorgestrel intrauterine system 8 (LNG-IUS 8; total content 13.5 mg) and subdermal etonogestrel implant (ENG) in a commercially-insured population in the US. Women's Health 2017: 25th Annual Congress, Washington DC, April 28-30, 2017. Poster.

79.   Deitelzweig S, Luo X, Gupta K, Trocio J, Mardeckian J, Curtice T, Lingohr-Smith M, Menges B, Lin J. Comparison of major bleeding risk among elderly nonvalvular atrial fibrillation patients treated with apixaban vs. rivaroxaban and dabigatran. Anticoagulation Forum, Los Angeles, CA, April 20-22, 2017. Poster

80.   Gupte-Sing K, Lin J, Lingohr-Smith M, Menges B, Rao S. Economic burden of patients with advanced melanoma in the US: comparisons by insurance types and geographic regions. AMCP Managed Care & Specialty Pharmacy Annual Meeting, Denver, CO March 27-30, 2017. Poster

81.   Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, Lingohr-Smith M, Menges B, Lin J. Real world evaluation of major bleeding risk and costs for all causes and bleeding-related health services among elderly patients with nonvalvular atrial fibrillation treated with apixaban or warfarin. American College of Cardiology 66th Annual Scientific Session, Washington, DC, March 17-19, 2017. Poster.

82.   Jabbour E, Lin J, Siegartel LR, Lingohr-Smith M, Menges B, Makenbaeva, D. Healthcare resource utilization and costs among patients with chronic myeloid leukemia after disease progression. 58th American Society of Hematology Annual Meeting, San Diego, CA. December 3-6, 2016. Poster.

83.   Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Lingohr-Smith M, Menges B, Lin J. Real-world evaluation of healthcare resource use and costs of elderly patients with nonvalvular atrial fibrillation treated with apixaban vs. warfarin in the US. American Heart Association Scientific Sessions, New Orleans, LA, November 12-16, 2016. Poster.

84.   Yu JS, Lynen R, Wang W, Law A. Trends and regional variations in contraceptive use among women in the United States based on the Center for Medicaid and Children's Health Insurance Program (CHIP) Services (CMCS) proposed quality measures. North American Forum on Family Planning. Contraception. 2016. Accepted for publication only.

85.   Deitelzweig S, Neuman RW, Lingohr-Smith M, Menges B, Lin J. Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors. American College of Emergency Physicians 2016 Research Forum, Las Vegas, NV, October 16-18, 2016. Poster.

86.   Law A, Yu JS, Wang W, Lin J, Lynen R. Use of nationally proposed quality measures to evaluate trends and variations in contraceptive use among commercially-insured women in the US. Academy of Managed Care Pharmacy’s Nexus Meeting, National Harbor, MD, October 3-6, 2016. Poster.

87.   Baxi, SS, Lingohr-Smith M, Menges, Lin J, Bobiak S. Real-world use of systemic treatments by line of therapy among patients with squamous cell carcinoma of the head and neck. Academy of Managed Care Pharmacy’s Nexus Meeting, National Harbor, MD, October 3-6, 2016. Poster.

88.   Deitelzweig S, Neuman R, Lingohr-Smith M, Lin J. Hospital resource utilization, cost and inpatient mortality associated with hospitalizations for major bleeding among atrial fibrillation patients treated with factor Xa inhibitors. European Society of Cardiology Congress, Rome, Italy, August 27-31, 2016. Poster.

89.   Liu Y, Skup M, Lin J, Chao J. Impact of non-medical switching on health care costs: a claims database analysis. American Academy of Dermatology Summer Meeting, Boston, MA, July 28, 2016. Encore Poster.

90.   Lingohr-Smith M, Aurora B, Lin J, Menges B. Makenbaeva D. Prevalence of Hodgkin lymphoma and relapsed or refractory Hodgkin lymphoma in the US. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 3-7, 2016. Accepted for publication only.

91.   Lin J, Lingohr-Smith M, Omar M, Chen C. Early discontinuation of combination therapy in multiple myeloma: A pilot analysis. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 3-7, 2016. Accepted for publication only.

92.   Survival of U.S. Medicare patients with multiple myeloma by line of therapy. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 3-7, 2016. Accepted for publication only.

93.   Carney P, Yao J, Lin J, Law A. Costs of hysteroscopic sterilization versus laparoscopic bilateral tubal ligation steriliation among commercially-insured women in the United States. ISPOR 21st International Meeting, Washington DC, May 21-25, 2016. Poster.

94.   Wen L, Divers C, Lingohr-Smith M, Lin J. Overview of national leading organizations involved in quality of care in oncology. ISPOR 21st International Meeting, Washington DC, May 21-25, 2016. Poster.

95.   Menges B, Deitelzweig C, Lin J, Lingohr Smith M, Lin G. Systematic review of novel therapeutic agents for treatment of hepatitis C virus infection in the US. ISPOR 21st International Meeting, Washington DC, May 21-25, 2016. Poster.

96.   Lin J, Lingohr-Smith M, Menges B, Makenbaeva D. Patterns of switching from imatinib to other BCR-ABL1 tyrosine kinase inhibitors among chronic myeloid leukemia patients in the US managed care setting. 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting, San Francisco, CA, April 19-22, 2016. Poster.

97.   Deitelzweig S, Evans M, Trocio J, Gupta K, Lingohr-Smith M, Menges B, Lin J. Impact of warfarin adherence status on healthcare costs among patients with nonvalvular atrial fibrillation. 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting, San Francisco, CA, April 19-22, 2016. Poster.

98.   Carney P, Yao J, Law A. Occurrence of pelvic pain post-procedure among women who have undergone female sterilization procedures-A retrospective claims analysis of commercially insured women in the U.S. Women's Health 2016: The 24th Annual Congress, Washington DC, April 16-19, 2016. Poster.

99.   Deitelzweig S, Gupta K, Nadkarni A, Trocio J, Lin J, Lingohr-Smith M. Hospital readmissions among patients with nonvalvular atrial fibrillation treated with the new oral anticoagulants, apixaban, dabigatran, and rivaroxaban. American College of Cardiology 65th Scientific Sessions, Chicago, IL, April 2-4, 2016. Poster.

100.       Mozaffari E, Lin J, Lingohr-Smith M. Incremental clinical and economic burden of cytomegalovirus infection among allogeneic hematopoietic cell transplant recipients. 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, Valencia, Spain, April 3-6, 2016. Poster.

101.       Lin J, Makenbaeva D, Bilmes R, Lingohr-Smith M, Wallis NT. Do adverse events related to tyrosine kinase inhibitor treatment among patients with chronic myelogenous leukemia represent a healthcare cost burden in the real-world setting? National Comprehensive Cancer Network Annual Conference, Hollywood, FL, March 31-April 2, 2016. Poster.

102.       Mozaffari E, Lin J, Lingohr-Smith M. Double-stranded DNA virus infections among allogeneic hematopoietic cell transplant recipients: impact on patient survival and hospital resource utilization. 2016 BMT Tandem Meetings, Honolulu, HI, February 18-22, 2016. Poster.

103.       Mozaffari E, Lin J, Lingohr-Smith M. Burden of cytomegalovirus infection among allogeneic hematopoietic cell transplant recipients. 2016 BMT Tandem Meetings, Honolulu, HI, February 18-22, 2016. Poster.

104.       Mozaffari E, Lin J, Lingohr-Smith M. Frequency of hospital readmissions post allogeneic hematopoietic cell transplantation. 2016 BMT Tandem Meetings, Honolulu, HI, February 18-22, 2016. Poster.

105.       Mozaffari E, Lin J, Lingohr-Smith M. Hospitalizations and mortality associated with dsDNA viral infections among hematopoietic cell transplant recipients. American Society of Hematology 57th Annual Meeting and Exposition, Orlando, FL, December 5-8, 2015.

106.       Spyropoulos AC, Preblick R, Kwong J, Lingohr-Smith M, Lin J. Is adherence to the American College of Chest Physicians recommended anticoagulation treatment duration associated with different outcomes among patients with venous thromboembolism? American Society of Hematology 57th Annual Meeting and Exposition, Orlando, FL, December 5-8, 2015. Poster.

107.       Lin J, Makenbaeva D, Bilmes R, Lingohr-Smith H, Wallis N. Economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors. American Society of Hematology 57th Annual Meeting and Exposition, Orlando, FL, December 5-8, 2015. Oral presentation.

108.       Mozaffari E, Lin J, Lingohr-Smith M. Burden of neutropenia-related hospital readmissions among hematopoietic cell transplant recipients.  50th ASHP Midyear Clinical Meeting and Exhibition, New Orleans, LA, December 6–10, 2015. Poster.

109.   Mozaffari E, Lin J, Lingohr-Smith M. Healthcare resource utilization and associated costs for hematopoietic cell transplant recipients: hospital perspective. 50th ASHP Midyear Clinical Meeting and Exhibition, New Orleans, LA, December 6–10, 2015. Poster.

110.   Li G, Kashyap S, Patkar AD, Seare JG, Yoo A. The long-term impact of bariatric surgery on metabolic comorbidities: A retrospective matched cohort database study. World Diabetes Congress, Vancouver, Canada, November 30-December 4, 2015. Poster.

111.       Fegelman E, Li G, Yoo A, Brethauer S. Bariatric surgery and end-organ metabolic and cardiovascular complications among obese patients: A retrospective matched cohort study using a US claims database. Obesity Week 2015, Los Angeles, CA, November 2-7, 2015. Poster.

112.   Law A, McCoy M, Lingohr-Smith M, Lin J, Lynen R. Economic Modeling of Cost Differences Associated with Use of Different Intrauterine Devices from a U.S. Payer Perspective. Academy of Managed Care Pharmacy (AMCP) Nexus 2015, Orlando, FL, October 26-29, 2015. Poster.

113.   Fan T, Lingohr-Smith M, Lin J. Real-world Medication Persistence and Outcomes Associated with Basal Insulin and GLP-1 Agonist Combination Therapy among Patients with Type 2 Diabetes in the US. Academy of Managed Care Pharmacy (AMCP) Nexus 2015, Orlando, FL, October 26-29, 2015. Poster.

114.       Mozaffari E, Lin J, Lingohr-Smith M. Frequency of Hospital Readmission Post Kidney Transplantation. American Society of Nephrology (ASN) Kidney Week 2015 Annual Meeting, San Diego, CA, November 5-8, 2015. Poster.

115.   Mozaffari E, Lin J, Lingohr-Smith M. Prevalence of Double Stranded DNA (dsDNA) Viral Infections Among Kidney Transplant Recipients. American Society of Nephrology (ASN) Kidney Week 2015 Annual Meeting, San Diego, CA, November 5-8, 2015. Poster.

116.   Mozaffari E, Lin J, Lingohr-Smith M. Prevalence of Double Stranded DNA Viral Infections Among Allogeneic Hematopoietic Stem Cell Transplant Recipients. Infectious Diseases Week, San Diego, CA, October 7–11, 2015. Poster.

117.   Mozaffari E, Lin J, Lingohr-Smith M. Hospital Readmissions Among Patients who Underwent Hematopoetic Stem Cell Transplantation (HCT). ICAAC/ICC, San Diego, CA, September 17–21, 2015. Poster.

118.   Carney P, Yao Jianying, Lin J, Law A. Comparison of Healthcare Costs Among Commercially-insured Women in the U.S. who Undergo Hysteroscopic Sterilization vs. Laparoscopic Bilateral Tubal Ligation Sterilization. 11th AAGL International Congress on Minimally Invasive Gynecological Surgery, Las Vegas, NV, November 15-18, 2015. Oral presentation.

119.   Lin J, Jhaveri M, Liao L, Kitio-Dschassi B, Lingohr-Smith M. Assessment of real-world efficacy and safety of basal insulin plus rapid-acting insulin vs. basal insulin treatment among patients with type 2 diabetes in the U.K. 51st European Association for the Study of Diabetes Annual Meeting, Stockholm, Sweden, September 15-18, 2015. Oral presentation.

120.   Law A, Wen L, Lin J, Tangirala M, Zampaglione E, Schwartz JS. A real-world assessment of out of pocket contraceptive costs before and after the implementation of the Affordable Care Act in the U.S. 143rd American Public Health Association (APHA) Annual Meeting and Exposition, Chicago, IL, October 31-November 4, 2015. Poster.

121.   Law A, Wen L, Lin J, Tangirala M, Schwartz JS, Zampaglione E. Are women benefiting from the Affordable Care Act? A real-world evaluation of the impact of the Affordable Care Act on out-of-pocket costs for contraceptives. 2015 North American Forum on Family Planning, Chicago, IL, November 14-16, 2015. Poster. 

122.   Kuritzky L, Lin J, Wysham C. Glucagon-like peptide 1 receptor agonist or rapid-acting insulin as add-on to basal insulin therapy in T2DM patients: 51st European Association for the Study of Diabetes Annual Meeting, Stockholm, Sweden, September 15-18, 2015. Poster.

123.   Kuritzky L, Lin J, Wysham C. Glucagon-like peptide 1 receptor agonist or rapid-acting insulin as add-on to basal insulin therapy in T2DM patients: A meta-analysis. American Diabetes Association 75th Scientific Sessions, Boston, MA, June 5-9, 2015. Poster.

124.   Yabe D, Ambos A, Cariou B, Duvnjak L, Evans M, Gonzalez-Galvez, G, Miharo H, Lin J, Nikonova EV, Pablos-Velasco P, Yale J, Ahren B. Efficacy of Lixisenatide in patients with type 2 diabetes: a post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials. Incretin 2015, Vancouver, CA, July 29-31, 2015. Poster.

125.   Wysham C, Lin J, Kuritzky. A meta-analysis of the safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes mellitus. ENDO 2015 Meeting of the Endocrine Society, San Diego, CA, March 5-8, 2015. Oral presentation.

126.       Deitelzweig S, Evans M, Hillson E, Trocio J, Bruno A, Tan W, Lingohr-Smith M, Lin J. A conservative approach to assess warfarin time-in-therapeutic ranges among nonvalvular atrial fibrillation patients in an integrated healthcare delivery setting in the U.S. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting, Philadelphia, PA, May 16-20, 2015, Poster

127.   Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M. Medical costs avoided with use of new oral anticoagulants vs. standard therapies or placebo among nonvalvular atrial fibrillation patients and venous thromboembolism patients. Academy of Managed Care Pharmacy 27th Annual Meeting and Expo, San Diego, CA, April 7-10, 2015. Poster.

128.   Deitelzweig S, Bruno A, Trocio J, Tate N, Lin J, Lingohr-Smith M. Real-world assessment of hospital readmission among hospitalized patients with nonvalvular atrial fibrillation treated with new oral anticoagulants – An early evaluation. Academy of Managed Care Pharmacy 27th Annual Meeting and Expo, San Diego, CA, April 7-10, 2015. Poster.

129.   Joshi K, Fu DJ, Lin J, Lingohr-Smith M, Fastenau J. Medical cost reductions for paliperidone palmitate versus placebo in randomized, double-blind trial of patients with schizoaffective disorder. Academy of Managed Care Pharmacy 27th Annual Meeting and Expo, San Diego, CA, April 7-10, 2015. Poster.

130.   Carney P, Lin J, Xia F, Law A. Evaluation of predictors of having hysteroscopic sterilization vs. laparoscopic bilateral tubal ligation in a Medicaid population. Academy of Women's Health 23rd Annual Congress, Washington, D.C., April 16-19, 2015. Poster.

131.   Deitelzweig S, Evans M, Hillson E, Trocio J, Bruno A, Tan W, Lingohr-Smith M, Lin J. Quality of warfarin therapy and its impact on healthcare resource utilization and costs among nonvalvular atrial fibrillation patients in an integrated delivery network setting in the U.S. Society of Hospital Medicine Annual Meeting, National Harbor, MD, March 29-April 1, 2015. Poster.

132.   Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M. Comparison of medical costs avoided when new oral anticoagulants are used for the treatment of patients with nonvalvular atrial fibrillation and venous thromboembolism vs. standard therapies in the U.S. Society of Hospital Medicine Annual Meeting, National Harbor, MD, March 29-April 1, 2015. Poster.

133.   Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M. Comparison of medical costs avoided among nonvalvular atrial fibrillation patients treated with dabigatran, rivaroxaban, apixaban, and edoxaban vs. warfarin. American College of Cardiology 64th Annual Scientific Sessions and Expo, San Diego, CA, March 14-16, 2015. Poster.

134.   Deitelzweig S, Evans M, Hillson E, Trocio J, Bruno A, Tan W, Lingohr-Smith M, Lin J. Does warfarin time-in-therapeutic range affect healthcare resource utilization and costs among nonvalvular atrial fibrillation patients in the U.S.? American College of Cardiology 64th Annual Scientific Sessions and Expo, San Diego, CA, March 14-16, 2015. Poster.

135.   Jabbour E, Makenbaeva D, Lingohr-Smith M, Lin J. Use of real-world claim databases to assess comorbidities relevant to the treatment of chronic myelogenous leukemia based on National Comprehensive Cancer Network Treatment Guidelines. National Comprehensive Cancer Network 20th Annual Conference, Hollywood, FL, March 12-14, 2015. Poster.

136.   Jabbour E, Makenbaeva D, Lingohr-Smith M, Lin J. Impact of genetic mutations on treatment response and costs related to tyrosine kinase inhibitor treatment among patients with chronic myelogenous leukemia. National Comprehensive Cancer Network 20th Annual Conference, Hollywood, FL, March 12-14, 2015. Poster.

137.   Deitelzweig S, Nutescu E, Meyer J, Lin J, Lingohr-Smith M, Amin A. Evaluation of differences in medical costs associated with venous thromboembolism prophylaxis with desirudin vs. low molecular weight heparin among patients undergoing total hip replacement surgery. American Society of Hematology 56th Annual Meeting, San Francisco, CA, December 6-9, 2014. Poster.

138.   Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M. Estimate of Real-world Medical Costs Avoidance when New Oral Anticoagulants are Used vs. Standard Therapy for the Treatment of Patients with Venous Thromboembolism in the U.S. American Society of Hematology 56th Annual Meeting, San Francisco, CA, December 6-9, 2014. Oral presentation.

139.   Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M. Comparison of medical costs avoided when new oral anticoagulants are used for the treatment of patients with atrial fibrillation and venous thromboembolism in the U.S. American Society of Hematology 56th Annual Meeting, San Francisco, CA, December 6-9, 2014. Poster.

140.   Jabbour E, Makenbaeva D, Lingohr-Smith M, Lin J. Evaluation of comorbidities relevant to tyrosine kinase inhibitor treatment among patients with chronic myelogenous leukemia in the U.S. managed care setting. American Society of Hematology 56th Annual Meeting, San Francisco, CA, December 6-9, 2014. Poster.

141.   Jabbour E, Makenbaeva D, Lingohr-Smith M, Lin J. Potential economic consequences of genetic mutations and restricted access to tyrosine kinase inhibitor treatments among patients with chronic myelogenous leukemia in the USA. American Society of Hematology 56th Annual Meeting, San Francisco, CA, December 6-9, 2014. Poster.

142.   Amin A, Jing Y, Trocio J, Lin J, Lingohr-Smith M, Graham J. Evaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial results. American Heart Association Scientific Sessions 2014. Chicago, IL, November 15-19, 2014. Poster.

143.   Amin A, Jing Y, Trocio J, Lin J, Lingohr-Smith M, Graham J. Evaluation of net clinical benefits of new oral anticoagulants for extended treatment of patients with acute venous thromboembolism. CHEST 2014, Austin, TX, October 25-30, Oral presentation.

144.   Woo V, Shaefer C, Brath H, DiGenio A, Lin J, Kumar KMP, Zisman A. Lixisenatide reduces BeAM value (difference between Bedtime (Be) and next-day pre-breakfast (AM) glucose: a clinical indicator for initiation of prandial therapy. Canadian Diabetes Association and the Canadian Society of Endocrinology and Metabolism 17th Annual CDA/CSEM Professional Conference and Annual Meetings, Winnipeg, Manitoba, October 22-25, 2014, Poster.

145.       Lin J, Zhou S, Wei W, Pan C, Lingohr-Smith M, Levin P. Does clinical inertia vary by personalized HbA1c goal? A study of predictors and prevalence of clinical inertia in a US managed care setting. European Association for the Study of Diabetes 50th Annual Meeting, Vienna, Austria, September 15-19, 2014, Poster.

146.       O'Neal DO, Umpierrez GE, DiGenio A, Goldenberg R, Hernandez-Triana E, Lin J, Park C, Renard E, Kovatchev B. Lixisenatide added to basal insulin reduces glycemic variability in patients with type 2 diabetes mellitus. European Association for the Study of Diabetes 50th Annual Meeting, Vienna, Austria, September 15-19, 2014, Poster.

147.   Amin A, Jing Y, Trocio J, Lin J, Lingohr-Smith M, Graham J. Incremental healthcare burden of bleeding among patients with venous thromboembolism in the US. International Society on Thrombosis and Haemostasis 60th Annual Meeting of the SSC, Milwaukee, WI, June 23-26, 2014, Poster.

148.   Amin A, Jing Y, Trocio J, Lin J, Lingohr-Smith M, Graham J. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among patients with venous thromboembolism based on clinical trial results. International Society on Thrombosis and Haemostasis 60th Annual Meeting of the SSC, Milwaukee, WI, June 23-26, 2014, Poster.

149.   Amin A, Jing Y, Trocio J, Lin J, Lingohr-Smith M, Graham J. Evaluation of net clinical benefits of new oral anticoagulants used for acute venous thromboembolism treatment vs. standard therapy. American Heart Association Quality of Care and Outcomes Research (AHA QCOR) Scientific Sessions, Baltimore, MD, June 2-4, 2014, Poster.

150.   Lin J, Zhou S, Pan C, Lingohr-Smith M. Is clinical inertia worsening among T2DM patients? Prevalence and predictors of clinical inertia in US managed care settings. American Diabetes Association (ADA) 74th Scientific Sessions, San Francisco, CA, June 13-17, 2014, Poster.

151.       Umpierrez G, DiGenio A, Goldenberg R, Hernandez-Triana E, Lin J, O'Neal D, Park C-Y, Renard E, Kovatchev B. Lixisenatide added to basal insulin reduces glycemic variability in T2DM patients. American Diabetes Association (ADA) 74th Scientific Sessions, San Francisco, CA, June 13-17, 2014, Poster.

152.       Lingohr-Smith M, Lin J. A dynamic health economics app: The budget impact of adopting the recently FDA approved hepatitis C therapy, sofosbuvir to a U.S. formulary. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting, Montreal, QC, Canada, May 31-Jun 4, 2014, Poster

153.       Lin J, Lingohr-Smith M. Comparison of insulin glargine vs. NPH insulin treatment among patients with type 2 diabetes based on review of clinical trial results. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting, Montreal, QC, Canada, May 31-Jun 4, 2014, Poster

154.       Lingohr-Smith M, Lin G. Health care costs associated with chronic hepatitis c infection in Europe. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress 2013, Poster

155.       Karson C, Offord S, Baker R, Eramo A, Lin J, Kamat S. Inpatient resource utilization and cost-related benefits of long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. American College of Neuropsychopharmacology (ACNP) Annual Meeting 2013, Poster

156.       O'Neal D, Charbonnel B, Wang E, Lin J, Davies, MJ, Fonseca V. Meta-analysis of randomized controlled trials of lixisenatide as add-on to basal insulin ± OADs in patients with type 2 diabetes mellitus. The Annual Scientific Meeting of the Australian Diabetes Society and Australian Diabetes Educators Association, 2013, Poster.

157.       Onishi Y, Inagaki N, Ikeda Y, Admane K, Lin J, Van Gaal L, Seino Y. Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus: a meta-analysis of 2 randomized controlled trials. European Association for the Study of Diabetes (EASD) Annual Meeting, 2013, Poster A-13-2244 EASD

158.       Hanefeld M, Berria R, Lin J, Aronson R, Darmon P, Evans M, Van Gaal L. Efficacy and safety of lixisenatide in elderly type 2 diabetes mellitus patients: subanalysis from the GetGoal programme. European Association for the Study of Diabetes (EASD) Annual Meeting, 2013, Poster A-13-1074 EASD

159.       Meier JJ, Yabe D, Wang E, Lin J, Rosenstock J, Ahren B. Efficacy of lixisenatide in patients with different levels of beta-cell function as assessed by C-peptide/glucose ratio. European Association for the Study of Diabetes (EASD) Annual Meeting, 2013, Poster A-13-929-EASD

160.       Puig Domingo ML, Fonseca V, Wang E, Lin J, Davies M, Tinahones FJ, Charbonnel B. Meta-analysis of randomized controlled trials of lixisenatide as add-on to basal insulin and/or oral antidiabetic drugs in patients with type 2 diabetes mellitus. European Association for the Study of Diabetes (EASD) Annual Meeting, 2013, Poster A-13-1044-EASD

161.       Raccah D, Ceriello A, Gourdy P, Sagnard L, Lin J, Rosenstock J. Meta-analysis of GLP-1 agonist lixisenatide use in patients insufficiently controlled with OADs. European Association for the Study of Diabetes (EASD) Annual Meeting, 2013, Poster A-13-807-EASD

162.       Wong B, Offord S, Mirski D, Zubek D, Lin J, Baker RA. Adherence, outcomes and the schizophrenia patient: data for case managers. CMSA's 23rd Annual Conference, 2013, Poster.

163.       Karson C, Kamat S, Offord S, Zubek D, Lin J, Eramo A, Gutierrez B. Impact of switching from oral to long-acting injectable antipsychotic medications among Medicaid-insured patients with schizophrenia. NCDEU 53rd Annual Meeting, 2013, Poster.

164.       Fonseca V, Wang E, Lin J, Guerci B, Evans M, Vidal J, Freemantle N. Basal insulin + lixisenatide induces less symptomatic hypoglycemia and weight gain than basal bolus. American Diabetes Association (ADA), 2013, Poster.

165.       Rosenstock J, Germe M, Wang E, Lin J, Bonadonna RC, de Pablos-Velasco P, Roussel R, Raccah D. Expanding the basal-plus regimen: basal insulin + lixisenatide is more likely to achieve the composite outcome of HbA1c<7%, no documented symptomatic hypoglycemia and no weight gain compared with basal + prandial insulin. American Diabetes Association (ADA), 2013, Poster.

166.       Charbonnel B, Wang E, Lin J, Davies M, Fonseca V. Meta-analysis of randomized controlled trials of lixisenatide as add-on to basal insulin in patients with type 2 diabetes mellitus. American Diabetes Association (ADA), 2013, Poster.

167.       Raccah D, Ceriello An Gourdy P, Sagnard L, Lin J, Rosenstock J. Meta-analysis of GLP-1 agonist lixisenatide use in patients insufficiently controlled with oral antidiabetic drugs suggest improved results in efficacy, hypoglycemia and weight gain. American Diabetes Association (ADA), 2013, Poster.

168.       Hanefeld M, Berria R, Lin J, Aronson R, Darmon P, Evans M, van Gaal L. Efficacy and safety of lixisenatide in elderly T2DM patients: subanalysis from the GetGoal program. American Diabetes Association (ADA), 2013, Poster.

169.       Seino Y, Inagaki N, Onishi Y, Ikeda Y, Admane K, Lin J, van Gaal L. Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus: a meta-analysis of 2 randomized controlled trials. American Diabetes Association (ADA), 2013, Poster.

170.       Zubek D, Wong B, Mirski D, Lin J, Offord S. Healthcare utilization findings important for nurses caring for patients with schizophrenia: poor early drug adherence negatively affects long-term patient outcomes. International Society of Psychiatric-Mental Health Nurses (ISPN), 2013, Poster.

171.   Zubek D, Wong B, Offord S, Baker RA, Mirski D, Lin J. Healthcare outcomes of patients with schizophrenia initiating long-acting injectable vs. oral antipsychotics: important implications for mental health nurses. International Society of Psychiatric-Mental Health Nurses (ISPN), 2013, Poster.

172.   Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Evaluation of medical costs associated with use of novel oral anticoagulants compared with warfarin among nonvalvular atrial fibrillation patients with moderate and high stroke risk. American Heart Association Quality of Care and Outcomes Research (AHA QCOR), 2013, Oral Presentation.

173.   Kim M, Bell KF, Makenbaeva D, Wiederkehr D, Lin G, Graham J. Healthcare burden associated with dyspepsia among nonvalvular atrial fibrillation patients. American Heart Association Quality of Care and Outcomes Research (AHA QCOR), 2013, Poster.

174.   Kim M, Makenbaeva D, Bell KF, Wiederkehr D, Lin G, Graham J. Impact of gastrointestinal disorders among nonvalvular atrial fibrillation patients on healthcare resource usage and costs. American Heart Association Quality of Care and Outcomes Research (AHA QCOR). 2013, Poster.

175.   Kamat S, Gutierrez B, Eramo A, Zubek D, Baker RA, Lin J, Karson C. Early assessment of real-world usage of second generation long-acting injectable paliperidone palmitate among commercially and Medicaid insured schizophrenia patients International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 2013, Poster.

176.   Karson C, Offord S, Zubek D, Kamat S, Docherty J, Lin J, Gutierrez B. Reduction of Hospitalizations and Costs among Medicaid Insured Schizophrenia Patients After Initiating Long-Acting Injectable Antipsychotics. American Psychiatric Association (APA), 2013, Poster.

177.   Kamat S, Zubek D, Offord S, Karson C, Docherty J, Lin J, Gutierrez B. Commercially Insured Schizophrenia Patients Use Fewer Inpatient Resources and Incur Lower Costs After Initiating Long-Acting Injectable Antipsychotics. American Psychiatric Association (APA), 2013, Poster.

178.   Schwartz DA, Eichner SF, Lin J, Skup M, Yang M, Mulani PM, Chao J. Comparison of Health Care Utilization and Costs Among Patients With Fistulizing Crohn’s Disease Treated With Biologics With or Without Prior Seton Procedure. European Crohn's and Colitis Organisation (ECCO), 2013, Poster.

179.   Bera R, Offord S, Zubek D, Lau G, Lin J, Baker RA, Karson C. Comparison of Healthcare Resource Usage and Costs Before and After Initiating Treatment with Long-Acting Injectable Antipsychotics among Medicaid Insured Schizophrenia Patients. Academy of Managed Care Pharmacy (AMCP), 2013, Poster.

180.   Wong B, Offord S, Mirski D, Zubek D, Lin J, Baker RA. Adherence, Outcomes and the Schizophrenia Patient: Data for Case Managers. Case Management Society of America (CMSA), 2013, Poster.

181.   Kim MH, Bell KF, Makenbaeva D, Wiederkehr D, Lin J and Graham J. Incremental Healthcare Burden Associated with Dyspepsia Among Nonvalvular Atrial Fibrillation Patients:  Implications for Anticoagulation Therapy.  International Stroke Conference (ISC), 2013, Poster.

182.   Karson C, Bera R, Offord S, Zubek D, Lau G and Lin J. Comparison of Healthcare Resource Usage and Costs Before and After Initiating  Long-Acting Injectable Antipsychotics among Medicaid Insured Patients with Schizophrenia. International Congress On Schizophrenia Research (ICOSR), 2013.

183.   Bera R, Karson C, Offord S, Zubek D, Lau G and Lin J. Persistent Usage of Long-Acting Injectable Antipsychotics is Associated with Reductions in Hospitalization Rates and Costs for Medicaid Insured Patients with Schizophrenia. International Congress On Schizophrenia Research (ICOSR), 2013.

184.   Karson C, Bera R, Offord S, Zubek D, Lau G and Lin J. Evaluation of Economic Healthcare Impact of Initiating Long-Acting Injectable Antipsychotic Therapy among Medicaid Insured Patients with Schizophrenia. American College of Neuropsychopharmacology (ACNP), 2012, Poster.

185.   Bera R, Karson C, Offord S, Zubek D, Lau G and Lin J. Impact on Hospitalization After Initiating Long-Acting Formulation Antipsychotics for a Longer vs. Shorter Time Period among Medicaid Insured Patients with Schizophrenia. American College of Neuropsychopharmacology (ACNP), 2012, Poster.

186.   Bera R, Offord S, Zubek D, Lau G, Lin J and Karson C. Impact on Healthcare Resource Usage and Costs among Medicaid Insured Schizophrenia Patients who Initiated Long-Acting Injectable Antipsychotics. U.S. Psychiatric and Mental Health Congress, 2012, Poster.

187.   Bera R, Offord S, Zubek D, Lau G, Lin J and Karson C. Evaluation of Hospitalization Resource Usage among Medicaid Insured Patients with Schizophrenia with Different Treatment Duration of Long-Acting Injectable Antipsychotic Therapy. U.S. Psychiatric and Mental Health Congress, 2012, Poster.

188.   Wong B, Offord S, Lin J and Mirski D. Early-on Discontinuation of Antipsychotic Therapy among Schizophrenia Patients is Predictive of Nonadherence Later on in the Course of the Illness. U.S. Psychiatric and Mental Health Congress, 2012, Poster.

189.   Offord S, Mirski D, Lin J and Wong B. Healthcare Impact of Schizophrenia Patients Initiating Long-Acting Injectable vs. Oral Antipsychotics. U.S. Psychiatric and Mental Health Congress, 2012, Poster.

190.   Schwartz DA, Eichner SF, Lin J, Skup M, Yang M, Mulani PM,  Chao J.  Comparison of health care utilization and costs among patients with fistulizing Crohn’s disease treated with biologics with or without prior seton procedure. American College of Gastroenterology (ACG), 2012, Poster.

191.   Cross R, Flasar M, Patil S, Lin J, Yang M, Mulani PM, Chao J. Use of Anti-TNF Agents in Crohn’s Disease Is Associated With Larger Reductions in Diagnostic Imaging and Radiation Doses Compared With Systemic Steroids in the Year Following Initiation of Therapy. American College of Gastroenterology (ACG), 2012, Poster.

192.   Lin J, Chow W, Mody S and Rupnow M. Real-world Evaluation of Adverse Event Related Outcomes in Hospitalized Patients using Tapentadol IR vs. Oxycodone IR. American Society of Regional Anesthesia and Pain Medicine (ASRA) 2012 conference, Poster.

193.   Lin J, Chow W, Kim M and Rupnow M. Early Evaluation of Patient Characteristics, Hospital Length of Stay and Costs among Users of Tapentadol IR and Oxycodone IR. American Society of Regional Anesthesia and Pain Medicine (ASRA) 2012 conference, Poster.

194.   Chase P, Wang E, Cali A, Dain M-P, Lin J, Garg S. Glycemic Control and Safety of Insulin Glargine Among Type 1 Diabetes Patients in the United States: An Analysis of the IMPACT Database. American Diabetes Association Middle East (ADA-ME) Annual conference, 2012, Oral Presentation.

195.   Cali A., Dailey G., Lin J., Wang E. Evaluation of a Basal-Bolus Regimen in Patients With Type 2 Diabetes Mellitus of Different Ages: A Pooled Analysis. World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy) 2012 conference, Poster.

196.   Dain M-P, Cali A., Del Prato S., Lankisch M., Lin J., Owens D.R., Dailey G. Evaluation of a Basal-Plus Regimen in Patients With Type 2 Diabetes Mellitus of Different Ages: A Pooled Analysis. World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy) 2012 conference, Poster.

197.   Chase P, Wang E, Cali A, Dain M-P, Lin J, Garg S. Efficacy and Safety of Insulin Glargine among Type 1 Diabetes Patients in the US: Analysis of the IMPACT Database. World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy) 2012 conference, Oral Presentation.

198.   Kadowaki T, Odawara M, Lin J, Ohtani T, Ito T, Admane K. Glycemic Control and Hypoglycemia Prevalence in Japanese Subjects With Type 2 Diabetes According to Age: An ALOHA Study Subanalysis. Chinese Diabetes Society (CDS) Annual conference, 2012, Poster.

199.   Pan C, Admane K, Zhang Q, Wang E, Lin J, Ning G. Analysis of Pooled Clinical Trial Data for Insulin Glargine vs NPH in Asian Insulin-Naïve Patients With Type 2 Diabetes. Chinese Diabetes Society (CDS) Annual conference, 2012, Poster.

200.   Wang J, Ji L, Shang S, Wang E, Lin J, Admane K. Glycemic Control and Hypoglycemia Prevalence in Chinese T2DM Patients Treated with Insulin Glargine or NPH: An Analysis of the FINE Asia Registry Population. Chinese Diabetes Society (CDS) Annual conference, 2012, Poster.

201.   Chiorean, M, Yang M, Lomax K, Rizzo J, Mulani P, Chao J. Reduction in Colectomy and Related Healthcare Costs in Ulcerative Colitis Patients Treated with Adalimumab Compared With Immunosuppressants or Steroids. Digestive Disease Week 2012, Poster.

202.   Ji L, Wang E, Lin J, Shang S, Admane K. Initiation of Basal Insulin in Chinese Patients With Type 2 Diabetes: An Analysis of the FINE Asia Registry. Chinese Diabetes Society (CDS) Annual conference, 2012, Poster.

203.   Yang J, Wang J, Admane K, Wang E, Lin J, Ji L. Predictors of Hypoglycemia in the Real-World Management of Asian Patients With T2DM: A FINE-Asia Registry Analysis. Chinese Diabetes Society (CDS) Annual conference, 2012, Poster.

204.   Yang Y, Wang E, Lin J, Shang S, Admane K, Ji L. Impact of Gender on Glycemic Control and Safety in the Management of Asian Patients With Type 2 Diabetes: A Subanalysis of the FINE-Asia Registry. Chinese Diabetes Society (CDS) Annual conference, 2012, Poster.

205.   Ning G, Wang E, Zhang Q, Lin J, Admane K. Analysis of Pooled Clinical Trial Data for Insulin Glargine vs NPH in Asian Insulin-Naïve Patients With Type 2 Diabetes Stratified by BMI. Chinese Diabetes Society (CDS) Annual conference, 2012, Poster.

206.   Fanelli CG, Porcellati F, Lin J, Wang E, Lucidi P, Bolli GB. Glycemic Control and Hypoglycemia Prevalence According to BMI: An Analysis of RCT Data. American Diabetes Association Middle East (ADA-ME) Annual conference, 2012, Oral Presentation.

207.   Odawara M, Admane K, Lin J, Wang E, Ohtani T, Kadowaki T. Glycemic Control and Hypoglycemia Prevalence by BMI in Japanese Patients With Type 2 Diabetes: ALOHA Study Sub-Analysis. International Diabetes Federation-Western Pacific Region (IDF-WPR) Conference 2012, Poster.

208.   Ohtani T, Kadowaki T, Admane K, Lin J, Wang E, Odawara M. Glycemic Control and Hypoglycemia Prevalence by Age in Japanese Subjects With Type 2 Diabetes: ALOHA Study Subanalysis. International Diabetes Federation-Western Pacific Region (IDF-WPR) Conference 2012, Poster.

209.   Pan C, Admane K, Zhang Q, Lin J, Wang E, Ning G. Pooled Clinical Trial Analysis of Insulin Glargine vs NPH in Insulin-Naïve Asian Patients With Type 2 Diabetes Mellitus. International Diabetes Federation-Western Pacific Region (IDF-WPR) Conference 2012, Poster.

210.   Wang J, Admane K, Wang E, Lin J, Ji L. Glycemic Control and Hypoglycemia Prevalence in Chinese T2DM Patients Treated with Insulin Glargine or NPH: FINE Asia. International Diabetes Federation-Western Pacific Region (IDF-WPR) Conference 2012, Poster.

211.   Ji L, Admane K, Lin J, Wang E, Wang J. Initiation of Basal Insulin in Chinese Patients With T2DM Inadequately Controlled by OADs: FINE Asia Registry Analysis. International Diabetes Federation-Western Pacific Region (IDF-WPR) Conference 2012, Poster.

212.   Wang J, Admane K, Wang E, Lin J, Ji L. Predictors of Hypoglycemia in the Real-World Management of Asian Patients With T2DM: A FINE-Asia Registry Analysis. International Diabetes Federation-Western Pacific Region (IDF-WPR) Conference 2012, Poster.

213.   Ji L, Admane K, Lin J, Wang E, Wang J. Impact of Gender on Glycemic Control and Safety in Managing Asian Patients With T2DM: A FINE-Asia Registry Subanalysis. International Diabetes Federation-Western Pacific Region (IDF-WPR) Conference 2012, Poster.

214.   Cali A, Dailey G, Lin J, Wang E. A pooled analysis of patients with type 2 diabetes mellitus to evaluate the efficacy and safety of a basal-bolus regimen across different age groups. European Association for the Study of Diabetes (EASD) 2012, Poster.

215.   Bolli GB, Porcellati F, Lin J, Cali A, Wang E, Dain MP, Lucidi P, Fanelli CG. Reduction in HbA1c and Hypoglycaemia Rates With Insulin Glargine vs NPH in Treatment-Naïve Patients with Type 2 Diabetes Stratified by BMI: Pooled Analysis of 6 Clinical Trials. European Association for the Study of Diabetes (EASD) 2012, Poster.

216.   Wong B, Mirski D, Offord S and Lin J. Among patients with schizophrenia non-adherence to antipsychotic medications early-on results in more hospitalizations and greater healthcare costs. International Early Psychosis Association (IEPA), 2012, Poster.

217.   Offord S, Lin J, Mirski D and Wong B. Schizophrenic patients who discontinue antipsychotic medications early-on have a greater likelihood of non-adherence later on in the course of the illness. International Early Psychosis Association (IEPA), 2012, Poster.

218.   Lin J, Chow W, Mody S and Rupnow M. Real-world Evaluation of Adverse Event Related Outcomes in Hospitalized Patients using Tapentadol IR vs. Oxycodone IR. PainWeek 2012, Poster.

219.   Lin J, Chow W, Kim M and Rupnow M. Early Evaluation of Patient Characteristics, Hospital Length of Stay and Costs among Users of Tapentadol IR and Oxycodone IR. PainWeek 2012, Poster.

220.   Wong B, Offord S, Mirski D and Lin J. Characteristics associated with antipsychotic drug adherence among schizophrenic patients in a US managed care environment. Institute on Psychiatric Services (IPS) 2012, Poster.

221.   Baker R, Wong B, Offord S, Mirski D and Lin J. Antipsychotic drug adherence correlates with hospitalization rates and length of stay among Medicare and non-Medicare schizophrenia populations. Institute on Psychiatric Services (IPS) 2012, Poster.

222.   Mirski D and Lin J, Offord S and Wong B. The severity and demographics of schizophrenia patients switching to Depot antipsychotic agents. Institute on Psychiatric Services (IPS) 2012, Poster.

223.   Lin J, Wong B, Offord S and Mirski D. Managed care cost savings associated with the use of long-acting injectable formulations of antipsychotic agents in schizophrenia. Institute on Psychiatric Services (IPS) 2012, Poster.

224.   Offord S, Mirski D, Lin J and Wong B. Drug compliance and associated outcomes in schizophrenia patients before and after the initiation of depot antipsychotic agents. Institute on Psychiatric Services (IPS) 2012, Poster.

225.   Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J and Graham J. Predicting Impact Of Warfarin’s Time-In-Therapeutic Range On Stroke And Major Bleed Rates And Its Influence On Medical Cost Avoidance Associated With NOAC Usage– Learning From RE-LY, ROCKET-AF And ARISTOTLE Trials. Thrombosis and Hemostasis Summit of North America (THSNA) 2012, Poster.

226.   Odawara M, Wang E, Lin J, Admane K, Ito T and Kadowaki T. Glycemic Control and Hypoglycemia Prevalence in Japanese Participants With Type 2 Diabetes According to BMI: A Sub-Analysis of the ALOHA Data. American Diabetes Association (ADA) Annual conference, 2012, Poster.

227.   Raccah D,  Lin J, Bahloul A, Wang E and Penfornis A. Meta-analysis of Efficacy and Safety Outcomes Associated with the Basal-Plus Regimen of Insulin Glargine and Insulin Glulisine among Type 2 Diabetes Patients with HbA1c ≥8%. American Diabetes Association (ADA) Annual conference, 2012, Publication only.

228.   Kautzky-Willer A, Kosi L, Mihaljevic R, Lin J and Wang E. Glycemic Control and Hypoglycemia Prevalence According to Gender: An Analysis of RCT Data. American Diabetes Association (ADA) Annual conference, 2012, Poster.

229.   Garg S, Lin J, Wang E and Chase P. Evaluating Overall Glycemic Management of People With Type I Diabetes in the US. American Diabetes Association (ADA) Annual conference, 2012, Publication only.

230.   Lin J, Wei W, Vlajnic A, Pan C, Xie L, Baser O and Levin P. Real-world Practice Pattern and Outcomes of Patients with Type 2 Diabetes (T2DM) Initiating Injectable Therapy via Insulin Glargine Disposable Pen (GLA-P) or Liraglutide (LIRA). American Diabetes Association (ADA) Annual conference, 2012, Poster.

231.   Levin P, Wei W, Vlajnic A, Pan C, Xie L, Lin J and Baser O. Real-world Outcomes of Initiating Injectable Therapy with Insulin Glargine or Liraglutide among Patients With Type 2 Diabetes. American Diabetes Association (ADA) Annual conference, 2012, Oral Presentation.

232.   Owens DR, Del Prato S, Lin J, Wang E and Lankisch M. Impact of Diabetes Duration on Efficacy and Safety of a Basal-plus Regimen of Insulin Glargine Plus Once Daily Insulin Glulisine: a Pooled Analysis From 4 Clinical Trials. American Diabetes Association (ADA) Annual conference, 2012, Publication only.

233.   Dailey G, Lin J and Wang E. Efficacy and Safety of a Basal-Bolus Regimen of Basal Insulin Plus Insulin Glulisine in Patients With Type 2 Diabetes: A Pooled Analysis of 5 Clinical Trials. American Diabetes Association (ADA) Annual conference, 2012, Poster.

234.   Del Prato S, Lankisch M, Lin J, Wang E and Owens DR. Efficacy and Safety of a Basal-Plus Regimen of Insulin Glargine Plus Insulin Glulisine in Patients With Type 2 Diabetes: A Pooled Analysis of 4 Clinical Trials. American Diabetes Association (ADA) Annual conference, 2012, Poster.

235.   Lankisch MR, Owens DR, Wang E, Lin J and Del Prato S. Basal-Plus Regimen of Insulins Glargine and Glulisine Is Weight Neutral Across BMI Groups. American Diabetes Association (ADA) Annual conference, 2012, Publication only.

236.   Fanelli CG, Porcellati F, Lin J, Wang E, Lucidi P and Bolli GB. Glycemic Control and Hypoglycemia Prevalence According to BMI: An Analysis of RCT Data. American Diabetes Association (ADA) Annual conference, 2012, Publication only.

237.   Little S, Wang E, Lin J, Home P and Shaw J. Factors Influencing Prevalence of Hypoglycemia in RCTs of Previously Insulin-Naive People With Type 2 Diabetes. American Diabetes Association (ADA) Annual conference, 2012, Publication only.

238.   Lucidi P, Porcellati F, Lin J, Wang E, Bolli GB and Fanelli CG. Efficacy and Safety of Insulin Glargine vs NPH Insulin in Subjects With Type 2 Diabetes Mellitus Uncontrolled on Oral Agents: A Pooled Analysis of RCT Data. American Diabetes Association (ADA) Annual conference, 2012, Poster.

239.   Chase P, Lin J, Wang E and Garg S. Treatment of People With Type I Diabetes in the US: The Impact Database. American Diabetes Association (ADA) Annual conference, 2012, Poster.

240.   Mirski D, Offord S, Wong B, Lin J and Ross BA. Impact Of Antipsychotic Drug Adherence On The Management Of Schizophrenia Among US Medicare Patients. NEDEU 2012 Conference, by American Society of Clinical Psychopharmacology, Poster.

241.   Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J and Graham J. Medical Cost Avoidance among the General and Elderly Atrial Fibrillation Populations Differs According to Specific Anticoagulant Use, Based on the ARISTOTLE and RE-LY Trials. AHA-Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2012, Poster.

242.   Offord S, Mirski D, Lin J and Wong B. Drug compliance and associated outcomes in schizophrenia patients before and after the initiation of depot antipsychotic agents. American Psychological Association (APA) 2012, Oral Presentation.

243.   Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J and Graham J. Evaluation of Total Medical Costs with the Use of Apixaban and Rivaroxaban vs. Warfarin Among Atrial Fibrillation Patients. AHA-Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2012, Poster.

244.   Dasta JF, Chiong JR, Christian R and Lin J. Evaluation of Cost Offset Associated with Tolvaptan Usage Among Hyponatremic SIADH Patients in the US, Based on the SALT-1 and SALT-2 Trials. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Annual Conference, 2012, Poster.

245.   Pan C, Tangirala K, Wei W and Lin J. Health outcomes of initiating basal analog insulin via disposable pens among patients with type-2 diabetes in a US national managed care plan. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Annual Conference, 2012, Poster.

246.   Deitelzweig S, Amin A, Lin J, Christian R, Baumer B, Lowe TJ. Impact of Hyponatremia on Healthcare Resource Utilization in Decompensated Cirrhosis Patients. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Annual Conference, 2012, Poster.

247.   Wong B, Offord S, Mirski D and Lin J. Characteristics associated with antipsychotic drug adherence among schizophrenic patients in a US managed care environment. American Psychological Association (APA) 2012, Poster.

248.   Baker R, Wong B, Offord S, Mirski D and Lin J. Antipsychotic drug adherence correlates with hospitalization rates and length of stay among Medicare and non-Medicare schizophrenia populations. American Psychological Association (APA) 2012, Poster.

249.   Mirski D and Lin J, Offord S and Wong B. The severity and demographics of schizophrenia patients switching to Depot antipsychotic agents. American Psychological Association (APA) 2012, Poster.

250.   Lin J, Wong B, Offord S and Mirski D. Managed care cost savings associated with the use of long-acting injectable formulations of antipsychotic agents in schizophrenia. American Psychological Association (APA) 2012, Poster.

251.   Offord S, Mirski D, Lin J and Wong B. Drug compliance and associated outcomes in schizophrenia patients before and after the initiation of depot antipsychotic agents. American Psychological Association (APA) 2012, Poster.

252.   Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J and Graham J. Total Medical Costs Avoided with Apixaban versus Aspirin Treatment Among Atrial Fibrillation Patients Unable or Unwilling to Take Warfarin, Based on the AVERROES Trial Results. 2012 American College of Cardiology (ACC), Oral Presentation.

253.   Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J and Graham J. Comparison of Total Medical Cost Avoidance with the Usage of New Oral Anticoagulants Instead of Warfarin Among Atrial Fibrillation Patients, Based on the ARISTOTLE, RE-LY and ROCKET-AF Trials. 2012 American College of Cardiology (ACC), Poster.

254.   Lin J, Xie L, Wei W, Zhou S, Miao R, Pan C, Baser O. An Empirical Approach to Measure and Predict Treatment Persistence Among Insulin-glargine-treated Patients with Type 2 Diabetes. American Managed Care Pharmacy (AMCP) Annual Conference, 2012, Poster.

255.   Lin J, Miao R and Wei W. Real-world outcomes of switching from vial/syringe to disposable pen among elderly patients with type 2 diabetes mellitus who were treated with insulin glargine. American Managed Care Pharmacy (AMCP) Annual Conference, 2012, Poster.

256.   Lin J, Dalal M, Connolly G and Khorana AA. Evaluation of venous thromboembolism (VTE) risk among ambulatory patients with pancreatic cancer in a real-world setting.  ASCO, 2012 Gastrointestinal Cancers Symposium, Poster.

257.   Wong B, Offord S, Mirski D and Lin J. Epidemiology of schizophrenia patients initiating long-acting injectable vs. oral antipsychotics among the US Medicare and non-Medicare patient populations. American Psychological Association (APA) 2012, Oral Presentation.

258.   Dasta JF, Chiong JR, Christian R, Lin J. Estimation of Cost Savings Associated with Tolvaptan-mediated Length of Stay (LOS) Reduction among SIADH Patients in the US, Based on SALT-1 and SALT-2 Trials. Society of Critical Care Medicine (SCCM), Annual Conference, 2012, Poster.

259.   Lin J, Ling J, Wei W, Pan C. Outcomes of Initiating Insulin Glargine Therapy with Disposable Pen or Vial Among Patients with Type 2 Diabetes in a US Managed Care Health Plan. Diabetes Technology Meeting, 2011, Poster.

260.   Lin J, Miao R, Wei W. Does device make a difference? A real-world study of switching from vial to disposable pen among an employee population with type 2 diabetes mellitus who were treated with insulin glargine. Diabetes Technology Meeting, 2011, Poster.

261.   Dasta JF, Chiong JR, Kim S, Lin J. Evaluation Of The Hospital Resource Utilization Associated With Tolvaptan Usage Among Heart Failure Patients With Hyponatremia From The Everest Trial. American College of Clinical Pharmacy (ACCP) Annual Conference, 2011, Poster.

262.   Chiong JR, Dasta JF, Kim S, Lin J. Evaluation of Cost Savings Associated with Tolvaptan-mediated Length of Stay Reduction among Heart Failure Patients with Hyponatremia in the US, Based on the EVEREST Trial. American College of Chest Physicians (ACCP)-CHEST 2011. Oral Presentation.

263.   Amin A, Deitelzweig S, Lin J, Belk K, Christian R, Baumer D. and Lowe T. Consequences of Hyponatremia on Cost and Length of Stay in Heart Failure Patients. Annual Scientific meeting of the Heart Failure Society of America (HFSA), 2011, Poster.

264.   Deitelzweig S, Amin A, Lin J, Belk K, Christian R, Baumer D. and Lowe T. Impact of Hyponatremia on Mortality and Readmission Rates in Hospitalized Patients with Heart Failure. Annual Scientific meeting of the Heart Failure Society of America (HFSA), 2011, Poster.

265.   Little S, Wang E, Lin J, Home P, Shaw J. Factors influencing prevalence of hypoglycaemia in RCTs of previously insulin-naive people with type 2 diabetes. International Diabetes Federation (IDF) Conference 2011, Poster.

266.   Lankisch MR, Owens DR, Wang E, Lin J, Del Prato S. Dose Change in a Basal-Plus Regimen of Insulins Glargine and Glulisine Across BMI Groups. International Diabetes Federation (IDF) Conference 2011, Poster.

267.   Lee B, Williams C, Nichols GA, Herson M, Jones E and Lin J. Real-World Data Collection and Measurement of a QI-CME Activity to Improve Diabetes Care in a MCO. ALLIANCE FOR CME Annual Conference 2012, Poster.

268.   Amin A, Deitelzweig S, Lin J, Christian R, Baumer D. and Lowe T. Effect of SIADH on patient outcomes and healthcare resource utilization in hospitalized patients. International Society of Pharmacoeconomics and Outcomes Research - ISPOR Annual European Congress, 2011, Poster.

269.   Ji L, Wang E, Lin J and Tsai S.Variation of Glycemic Control and Patient Comorbidities With Duration of Type 2 Diabetes in Asian Patients: Analysis of the FINE Asia Registry. International Diabetes Federation (IDF) Conference 2011, Poster.

270.   Little S, Wang E, Lin J, Home P, Shaw J. Glycaemic Control and Hypoglycaemia Prevalence With Insulin Glargine versus NPH Insulin According to BMI: An Analysis of Pooled RCT Data. International Diabetes Federation (IDF) Conference 2011, Poster.

271.   Tsai S, Wang E, Lin J and Ji L. Differences in Dose, HbA1c, and Hypoglycaemia Between Insulin Therapies According to BMI:  A FINE Asia Subanalysis. International Diabetes Federation (IDF) Conference 2011, Poster.

272.   Reynolds MR, Zimetbaum PJ, Lin J, Jhaveri M, Mozaffari E and Plich A. Estimation of potential cost savings associated with reduced rates of cardiovascular hospitalization among atrial fibrillation/flutter patients treated with dronedarone in the ATHENA trial. Annual Meeting of the Society for Medical Decision Making 2011, Oral Presentation.

273.   Wang E, Lin J, Dain M and Dailey G. Differences in Glycaemic Reductions Between Insulin Therapies According to Body Mass Index: Pooled Results from Multinational Clinical Trials.  European Association for the Study of Diabetes (EASD) 2011, Poster.

274.   Lin J, Lepercq J, Hall G, Dain M, Riddle M, Home P. A Meta-Analysis of Maternal Outcomes in Pregnant Women Using Insulin Glargine Compared With NPH Insulin. European Association for the Study of Diabetes (EASD) 2011, Poster.

275.   Suastika K, Tsai S, Wang J, Kiat K, Wang E, Lin J, Ji L. Baseline Characteristics of the First Basal Insulin Evaluation in Asia (FINE Asia) Study Population. European Association for the Study of Diabetes (EASD) 2011, Poster.

276.   Wang J, Ji L, Suastika K, Kiat K, Wang E, Lin J, Tsai S. Initiation of Basal Insulin in Patients With Type 2 Diabetes: National Differences in Glycemic Control After 6 Months in a Subanalysis of the FINE Asia Database. European Association for the Study of Diabetes (EASD) 2011, Poster.

277.   Ji L, Suastika K, Wang J, Kiat K, Wang E, Lin J, Tsai S. Factors Associated with HbA1c Reduction in Asian Patients With T2DM: An Analysis of the FINE Asia Registry. European Association for the Study of Diabetes (EASD) 2011, Poster.

278.   Lin J, Khorana AA, Dalal M, Connolly G. Clinical and Economic Burden of Venous Thromboembolism Among U.S. Ambulatory Cancer Patients Undergoing Chemotherapy. Annual Congress of The International Society on Thrombosis and Haemostasis (ISTH), 2011, Poster.

279.   Khorana AA, Dalal M, Lin J, Connolly G. Venous Thromboembolism (VTE) in the Cancer Outpatient Setting: Contemporary Rates and Predictors in the U.S.  Annual Congress of The International Society on Thrombosis and Haemostasis (ISTH), 2011, Poster.

280.   Khorana AA, Connolly G, Dalal M, Lin J. Does bevacizumab increase the risk of venous thromboembolism? A cohort study. American Society of Clinical Oncologists (ASCO), 2011, Poster.

281.   Connolly G, Dalal M, Lin J, Khorana AA. Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. American Society of Clinical Oncologists (ASCO), 2011, Poster.

282.   Reynolds M, Zimetbaum PJ, Diamand F, Jhaveri M, Lin J, Plich A. US Cost Savings Resulting From The Dronedarone-Associated Reduction In Cardiovascular Hospitalizations Among Atrial Fibrillation/Flutter Patients In The ATHENA Trial: Full Study Analysis. AHA-Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2011, Poster.

283.   Alpert JS, Guerin A, Lin J, Jhaveri M and Wu EQ. Treatment Persistence Among Atrial Fibrillation/Flutter Patients on Combination Warfarin and Antiarrhythmic Drug Therapy in the Real-World Setting. AHA-Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2011, Poster.

284.   Joish V, Boklage S, Lin J, Lynen R. Use of drospirenone/ethinyl estradiol in women may reduce acne-related healthcare costs.  National Association of Nurse Practitioners in Women’s Health 14th Annual Premier Women’s Health Care Conference, 2011, Poster.

285.   Lepercq J, Lin J, Hall G, Dain M, Riddle M, Home P. Maternal and Neonatal Outcomes in Pregnant Women Treated With Insulin Glargine versus NPH Insulin: A Meta-Analysis of Published Studies.  American Diabetes Association (ADA) Annual conference, 2011, Poster.

286.   Amin A, Varker H, Lin J, Thompson S and Johnston S. Duration of Risk of VTE in US Medical Patients. Society of General Internal Medicine (SGIM) Annual Conference, 2011, Poster.

287.   Amin A, Jhaveri M and Lin J. Rehospitalization Rates and Costs in Hospitalized ATHENA-Like Patients With Atrial Fibrillation/Atrial Flutter. Society of General Internal Medicine (SGIM) Annual Conference, 2011, Poster.

288.   Deitelzweig S, Amin A, Lin J, Belk K, Baumer D. and Lowe T. Impact Of Hyponatremia On Patient Outcomes And Health-Care Resource Utilization In Hospitalized Patients. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Annual Conference, 2011, Poster.

289.   Dasta JF, Chiong JR, Kim S, Lin J, Evaluation Of The Hospital Resource Utilization Associated With Tolvaptan Usage Among Heart Failure Patients With Hyponatremia From The Everest Trial. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Annual Conference, 2011, Poster.

290.   Amin A, Princic N, Lin J, Thompson S and Johnston S. Duration of Risk of Venous Thromboembolism in Real-World US Surgical Patients. Anticoagulation Forum’s 11th National Conference on Anticoagulant Therapy, 2011, Poster.

291.   Amin A, Jhaveri M and Lin J. Rehospitalization Rates and Costs in Hospitalized ATHENA-Like US Patients With Atrial Fibrillation/Atrial Flutter.  Heart Rhythm Society (HRS) Conference, 2011. Oral Presentation.

292.   Amin A, Jhaveri M and Lin J. Cost Burden to US Payers of ATHENA-Like Patients With Atrial Fibrillation/Atrial Flutter. Heart Rhythm Society (HRS) Conference, 2011, Poster.

293.   Deitelzweig S, Thompson S, Lin J, McMorrow D and Johnson BH. Impact of CMS VTE Hospital Acquired Conditions (HAC) Policy on Hospital Cost and Revenue associated with Major Surgical Hip and Knee Procedures. 2011, Annual Meeting of Society of Hospital Medicine (SHM).

294.   Amin A, Deitelzweig S, Lin J, Belk K, Baumer D. Impact of Hyponatremia on Patient Outcomes and Health-Care Resource Utilization in Hospitalized Patients. 2011, Annual Meeting of Society of Hospital Medicine (SHM).

295.   Deitelzweig S, Amin A, Lin J, Baumer D, Belk K. Impact of hyponatremia on the readmission rates of hospitalized patients. 2011, Annual Meeting of Society of Hospital Medicine (SHM).

296.   Amin A, Varker H, Princic N, Lin J, Thompson S and Johnston S.  Duration of risk of venous thromboembolism in patients hospitalized for medical illnesses in the USA. 2011, Annual Meeting of Society of Hospital Medicine (SHM).

297.   Kim MH, Smith PJ, Jhaveri M, Lin J, Klingman D. Amiodarone and Sotalol in Atrial Fibrillation: Treatment Persistence and Occurrence of Adverse Events in the Real-World Setting 2011 American College of Cardiology (ACC).

298.   Alpert JS, Guerin A, Lin J, Jhaveri M and Wu EQ. Evaluation of International Normalized Ratio Monitoring and Anticoagulation Control in Atrial Fibrillation/Flutter Patients Using Warfarin and Antiarrhythmic Drug Therapy. 2011 American College of Cardiology (ACC).

299.   Guerin A, Lin J, Jhaveri M, Wu E and Alpert J. Real-World Clinical Outcomes and Costs in Atrial Fibrillation/Flutter Patients on Combined Warfarin and Antiarrhythmic Drug Therapy. American Managed Care Pharmacy (AMCP) Annual Conference, 2011, Poster.

300.   Amin A, Princic N, Lin J, Thompson S and Johnston S. Real-World Analysis of the Duration of Risk of Venous Thromboembolism In US Surgical Patients. 2010 Annual Meeting of the American Society of Hematology (ASH). Oral Presentation.

301.   Amin A, Lin J and Wiederkehr D. Real-World Analysis of Venous Thromboembolism Rates and Thromboprophylaxis Prescribing In US Patients with Cancer. 2010 Annual Meeting of the American Society of Hematology (ASH).

302.   Deitelzweig S, Thompson S, Lin J, McMorrow D and Johnson BH. Impact of CMS VTE Hospital Acquired Conditions (HAC) Policy on Hospital Cost and Revenue associated with Major Surgical Hip and Knee Procedures. 2010 Annual Meeting of the American Society of Hematology (ASH).

303.   Naccarelli GV, Johnston SS, Dalal M, Lin J and Patel PP. High Cost Burden of Atrial Fibrillation/Atrial Flutter in Older Patients (≥65 years) in the United States. American Heart Association Scientific Sessions (AHA) 2010.

304.   Amin A, Lin J and Wiederkehr D. Real-world Analysis of Deep Vein Thrombosis Prevention in Patients with Severe Lung Disease. American College of Chest Physicians (ACCP)-CHEST 2010.

305.   Amin A, Lin J and Wiederkehr D. Readmission for Venous Thromboembolism in US Patients Following Hospitalization for Major Orthopedic Surgery. American College of Surgeons (ACS) 2010 Clinical Congress. Oral Presentation.

306.   Amin A, Lin J and Wiederkehr D. Inpatient and Outpatient Rates of Venous Thromboembolism and Thromboprophylaxis in US Patients following Major Abdominal Surgery. American College of Surgeons (ACS) 2010 Clinical Congress.

307.   Amin A, Lin J and Wiederkehr D. Prevention of Deep-Vein Thrombosis across the Continuum Care in Patients with Congestive Heart Failure in the US. 14th Annual Scientific meeting of the Heart Failure Society of America (HFSA), 2010.

308.   Schulman KL, Johnston SS, Lin J and Huse D. Prevalence of Atrial Fibrillation (AF) in the US. 26th International Conference on Pharmacoepidemiology & Theraputic Risk Management, 2010.

309.   Deitelzweig S, Lin J, Johnson, BH and Schulman KL. Trends In The Prevalence Of Venous Thromboembolism In The United States. 21st International Thrombosis Congress, 2010. BEST POSTER AWARD.

310.   Amin A, Lin J and Wiederkehr D. Prevention Of Venous Thromboembolism In At-Risk Medical Patients In the USA. 21st International Thrombosis Congress, 2010.

311.   Amin A, Lin J and Wiederkehr D. Real-World Analysis of Venous Thromboembolism Prevention in US Patients with Ischemic Stroke. 135th Annual Meeting of the American Neurological Association, 2010.

312.   Pineo G, Lin J, Stern L, Subrahmanian T. Robust Univariate And Multivariate Sensitivity Analysis Confirm That Enoxaparin Is Costsaving To The Payers Compared With Ufh For Vte Prevention In Patients With Ischemic Stroke: Analysis Of The Prevail Data. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, 2010. 

313.   Emons MF, Lin J, Yu HT. Treatment Patterns In Atrial Fibrillation: Agents Used In Current Patient Management. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, 2010. 

314.   Emons MF, Lin J, Yu HT. Inpatient Mortality And Hospitalization Costs In Atrial Fibrillation Patients. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, 2010.

315.   Naccarelli GV, Varker H, Lin J and Schulman K. Effect of Ethnicity on Prevalence of Atrial Fibrillation Among Medicaid Patients. Heart Rhythm Society (HRS) Conference, 2010.

316.   Kim MH, Lin J, Foltz Boklage SH and Kreilick CA. Comparative Cost Of Ablation In Atrial Fibrillation Patients Stratified By Procedural Success Versus Failure: Implications For Resource Utilization In Medicare-Aged Ablation Candidates In The United States. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, 2010.  Oral Presentation.

317.   Schulman KL, Johnston SS, Lin J and Huse D. Projecting Disease Prevalence: The Impact Of Methodology– Examples In Atrial Fibrillation, International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, 2010.  Workshop Panel Lead.

318.   Deitelzweig S, Lin J and Lin G. Preventing venous thromboembolism following hip replacement surgery: analysis of special populations who require alterations to anticoagulant regimens. 2010, Annual Meeting of Society of Hospital Medicine (SHM).

319.   Kim, M.H., Lin J, Chu, BC and Schulman, KL. Total Healthcare Costs Among Atrial Fibrillation Patients in the United States in 2010. 2010 American College of Cardiology (ACC).

320.   Kim, M.H., Johnson, SS, Lin J and Schulman, KL. Estimate of Incremental Cardiovascular Healthcare Costs in Patients with Atrial Fibrillation in the United States. 2010 American College of Cardiology (ACC).

321.   Amin A, Lin J and Ryan A. VTE Prophylaxis Across the Continuum of Care in US Orthopedic Surgery Patients. 2009 Annual Meeting of the American Society of Hematology (ASH).

322.   Deitelzweig S, Lin J, Johnson, BH and Schulman KL. Prevalence of Venous Thromboembolism Across Ethnic Groups in the United States. 2009 Annual Meeting of the American Society of Hematology (ASH).

323.   Merli GJ, Malangone E, Lin J and Stern L. Real-world VTE prophylaxis practices in US orthopedic surgery patients: an analysis of an integrated healthcare database. 2009 Annual Meeting of the American Society of Hematology (ASH).

324.   Amin A, Lin J and Ryan A. VTE Prophylaxis Across the Continuum of Care in US Medical Patients at Risk of Venous Thromboembolism. 2009 Annual Meeting of the American Society of Hematology (ASH).

325.   Deitelzweig S, Lin J, Johnson BH, Schulman KL. Current trends and future projections on the prevalence of venous thromboembolism in the USA, National Conference on Blood Disorders in Public Health, 2009. Oral Presentation.

326.   Patel PP, Johnston SS, Lin J, Schulman KL, Naccarelli GV Hospitalization And Mortality In Advanced-Age Patients With Atrial Fibrillation/Atrial Flutter But Without Heart Failure In The United States. International Society of Pharmacoeconomics and Outcomes Research - ISPOR 12th Annual European Congress, 2009

327.   Patel PP, Naccarelli GV, Johnston SS, Lin J, Schulman KL Cost Burden Of Athena Endpoints In Athena-Like Patients With Atrial Fibrillation/Atrial Flutter But Without Heart Failure In The United States.  International Society of Pharmacoeconomics and Outcomes Research - ISPOR 12th Annual European Congress, 2009

328.   Amin AN, Lin J, Johnson BH, Schulman KL Economic Outcomes in Patients at Risk of Venous Thromboembolism Receiving Best-Practice Appropriate Prophylaxis or Partial Prophylaxis, American College of Chest Physicians (ACCP) Annual Conference, 2009

329.   Amin AN, Lin J, Ryan A. VTE Prophylaxis Across the Continuum of Care in US Medical and Surgical Patients at Risk of Venous Thromboembolism. American College of Chest Physicians (ACCP) Annual Conference, 2009

330.   Amin AN and Lin J. Hospital Acquired Venous Thromboembolism Rates Following Prophylaxis with Enoxaparin and Dalteparin. American College of Chest Physicians (ACCP) Annual Conference, 2009

331.   Amin A, Lin J and, Ryan A. Analysis of inpatient and outpatient venous thromboembolism prophylaxis patterns in US critical care patients. American College of Chest Physicians (ACCP) Annual Conference, 2009. Oral Presentation.

332.   Deitelzweig S, Lin J, Johnson BH, Schulman KL. Prevalence Of Venous Thromboembolism In The Usa: Now And Future.  XXII Congress of The International Society on Thrombosis and Haemostasis (ISTH), 2009. Oral Presentation.

333.   Pineo G, Lin J, Stern L, Subrahmanian T. Enoxaparin Is Cost-Saving Compared With Unfractionated Heparin (Ufh) For Venous Thromboembolism Prophylaxis In Patients With Acute Ischemic Stroke: An Analysis Of Hospital Costs From The Prevail Trial.  XXII Congress of The International Society on Thrombosis and Haemostasis (ISTH), 2009

334.   Amin AN, Hussein M, Battleman D, Lin J, Stemkowski S, Merli G. Appropriate Vte Prophylaxis, Compared With Partial Vte Prophylaxis, Leads To Lower Vte Recurrence And Cost In Us Medical Patients.  XXII Congress of The International Society on Thrombosis and Haemostasis (ISTH), 2009

335.   Pineo G, Lin J, Stern L, Subrahmanian T. Enoxaparin For Venous Thromboembolism (VTE) Prophylaxis In Patients With Acute Ischemic Stroke Is Associated With Lower Costs To The Payers Than Unfractionated Heparin (UFH): Analysis From The Prevail Trial.  XXII Congress of The International Society on Thrombosis and Haemostasis (ISTH), 2009

336.   Amin, A., Lin J. and Ryan A. VTE prophylaxis across the continuum of care in US cancer patients. Publication-only. American Society of Clinical Oncologists (ASCO), 2009

337.   Kim, M.H., Lin J., Hussein, M., Kreilick, C. and Battleman D. How Much Does it Cost to Manage Atrial Fibrillation in the United States? AHA-Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2009

338.   Kim, M.H., Lin J. and Kreilick C. A National Assessment of Medicare Prescription Coverage Gaps Among Atrial Fibrillation Patients. AHA-Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2009

339.   Patel, P.P., Gregory, C., Lin J., Schulman, K.L. and Naccarelli, G.V. Hospitalization and Mortality in Patients With Atrial Fibrillation/Atrial Flutter and Among ATHENA-Like Patients in the United States. AHA-Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2009

340.   Patel, P.P., Johnston, S.J., Lin J., Schulman, K.L. and Naccarelli, G.V. Cost Burden of Hospitalization and Mortality in United States Atrial Fibrillation/Flutter Patients. Heart Rhythm Society (HRS) Conference, 2009

341.   Naccarelli, G.V., Johnston, S.J., Lin J., Patel, P.P. and Schulman, K.L. Cost Burden of ATHENA Endpoints in United States Atrial Fibrillation/Atrial Flutter Patients. Heart Rhythm Society (HRS) Conference, 2009

342.   Thosani, A.J., Xiong, Y., Lin J., Kothawala, P. and Zimetbaum, P.J. Are Atrial Fibrillation Patients Receiving Anticoagulation in Accordance With Their Stroke Risk?  Heart Rhythm Society (HRS) Conference, 2009

343.   Amin A.N., Lin J., Johnson B., Schulman K.L. Clinical Outcomes in Patients at Risk of Venous Thromboembolism Receiving Appropriate or Partial Prophylaxis. American Thoracic Society (ATS) International Conference, 2009

344.   Kim, M.H.,  Klingman, D., Lin J., Battleman, D. Incidence and Temporal Pattern of Hospital Readmissions for Atrial Fibrillation in Managed Care Patients Following Prior Hospitalization for this Condition. American Managed Care Pharmacy (AMCP) Annual Conference, 2009

345.   Kim M., Klingman D., Lin J., Battleman D. Patterns and predictors of discontinuation of rhythm-control therapy in patients with newly diagnosed atrial fibrillation.  American College of Cardiology (ACC), 2009

346.   Kim M., Klingman D., Lin J., Battleman D. What's the price for maintaining normal sinus rhythm? - Economics of prerequisite admission for antiarrhythmic drug initiation in atrial fibrillation. American College of Cardiology (ACC), 2009

347.   Naccarelli G.V., Varker H., Lin J., Schulman K. Increasing prevalence of atrial fibrillation and flutter in the United States: is it just due to the population aging? American College of Cardiology (ACC), 2009

348.   Ishak K.J., Proskorovsky I., Guo S., Lin J., Caro J.J. The impact of drug-related side-effects on persistence with amiodarone or sotalol in the management of atrial fibrillation: An exploratory analysis. AHA-49th Cardiovascular Disease Epidemiology and Prevention, 2009

349.   Deitelzweig S., Hussein M., Lin J., Kreilick C., Battleman D. Patterns and Predictors of Warfarin Use in Patients with Venous Thromboembolism. 2008 Annual Meeting of the American Society of Hematology (ASH).

350.   Spyropoulos A.C., Hussein M., Lin J., Battleman D. Rates of Venous Thromboembolism in Commercially Insured US Surgical Patients. 2008 Annual Meeting of the American Society of Hematology (ASH). Oral Presentation.

351.   Amin A.N., Lin J., Lenhart G., Schulman K.L. Economic Outcomes in Patients at Risk for Venous Thromboembolism Receiving Appropriate Enoxaparin or Unfractionated Heparin Prophylaxis. 2008 Annual Meeting of the American Society of Hematology (ASH).

352.   Amin A.N., Lin J., Yang G. and Stemkowski S. Clinical and Economic Outcomes Following Full or Partial ACCP Recommended Prophylaxis in Cancer Patients at Risk of Venous Thromboembolism.  2008 Annual Meeting of the American Society of Hematology (ASH). Oral Presentation.

353.   Amin, A.N., Hussein M., Battleman D., Lin J., Stemkowski S. and Merli G.J. Appropriate VTE Prophylaxis Is Associated with Lower Direct Medical Costs among Medical and Surgical Patients in the United States. 2008 Annual Meeting of the American Society of Hematology (ASH).

354.   Ishak K.J., Proskorovsky I., Guo S., Lin J., Caro J.J. Impact of non-persistence with amiodarone or sotalol on recurrence of atrial fibrillation. International Society For Pharmacoeconomics and Outcomes Research (ISPOR) European Congress 2008.

355.   Deitelzweig S., Lin J., Hussein M., Battleman D. Are surgical patients at-risk of venous thromboembolism currently meeting the surgical care improvement performance measure for appropriate and timely prophylaxis? American College of CHEST Physicians (ACCP) 2008 Meeting.

356.   Spyropoulos A.C., Hussein M., Lin J., Battleman D. Rates of venous thromboembolism occurrence in medical patients among the insured population. American College of CHEST Physicians (ACCP) 2008 Meeting.

357.   Merli G., Ferrufino C., Lin J., Hussein M., Battleman D. Total hospital-based costs of enoxaparin or fondaparinux prophylaxis in patients at risk of venous thromboembolism. American College of CHEST Physicians (ACCP) 2008 Meeting.

358.   Amin, A., Lin J., Yang, G and Stemkowski, S. Examining the rate of appropriate, ACCP-recommended VTE prophylaxis use in heart failure patients.  September 2008, 12th Annual Scientific Meeting of Heart Failure Society of America.

359.   Merli, G., Ferrufino, C., Lin J., Hussein, M., Battleman, D. Hospital-based Costs of Venous Thromboembolism Prophylaxis in Hospitalized Patients: a Retrospective Transactional Records Analysis, May 2008, Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, sponsored by the American Heart Association (AHA)/American Stroke Association.

360.   Amin, A., Yang, G, Lin J. and Stemkowski, S. Rates of guideline-recommended venous thromboembolism prophylaxis in US hospital patients, April 2008, Annual Meeting of Society of Hospital Medicine (SHM).

361.   Deitelzweig S., Lin J., Becker R., Benner J.  2-year costs of enoxaparin prophylaxis, unfractionated heparin prophylaxis, or no prophylaxis in medical patients at risk of venous thromboembolism. 2008 Annual Meeting of Society of Hospital Medicine (SHM).

362.   Amin, A., Yang, G, Lin J. and Stemkowski, S. Are hospitalized US medical patients receiving appropriate VTE prophylaxis? 2008, Annual Meeting of Society of General Internal Medincine( SGIM).

363.   Amin, A., Lin J., Yang, G and Stemkowski, S. VTE prophylaxis use in severe lung disease patients, 2008, Annual Meeting of American Thoracic Society (ATS).

364.   Amin, A., Lin J., Yang, G and Stemkowski, S. Rates of guideline-recommended venous thromboembolism prophylaxis in US hospital critical care patients, 2008, Annual Scientific Session of American College of Cardiology (ACC).

365.   Deitelzweig S., Becker R., Lin J., Benner J.  Comparison of the 2−Year Clinical Outcomes of VTE Prophylaxis Options in Medical Patients at Risk of VTE. 2007 Annual Meeting of the American Society of Hematology (ASH).

366.   Amin, A., Stemkowski, S., Lin J. and Yang, G. Rates of Guideline-Recommended Venous Thromboembolism Prophylaxis in Surgical Patients Among US Hospitals: A Real-World Analysis. 2007 Annual Meeting of the American Society of Hematology (ASH).

367.   Merli, G., Ferrufino, C., Lin J. and Hussein M. Low Molecular Weight Heparin Reduces the Cost of Venous Thromboembolism Treatment Compared with Unfractionated Heparin in US Hospitals. 2007 Annual Meeting of the American Society of Hematology (ASH).

368.   Deitelzweig S., Becker R., Lin J., Benner J.  Identifying VTE prophylaxis-related costs and outcomes, 19th Annual National Forum, Institute for Healthcare Improvement (IHI).

369.   Amin, A., Stemkowski, S.A., Lin J., and Yang G. (June 2007) Assessing adherence to the American College of Chest Physicians’ recommendations for thromboprophylaxis in hospitalized cancer patients, American Society of Clinical Oncology (ASCO) 2007 Annual Meeting.

370.   Merli, G., Ferrufino, C., Lin J. and Hussein M. (May 2007)  Venous Thromboembolism (VTE) Treatment With Low Molecular Weight Heparin Reduces Total Hospital Costs And VTE-Related Readmission, 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, sponsored by the American Heart Association (AHA)/American Stroke Association.

371.   Stemkowski, S.A., Lin J., Yang G. and Amin, A. (May 2007) VTE Prophylaxis in US Hospitals, 8th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, sponsored by the American Heart Association (AHA)/American Stroke Association.

372.   Amin, A., Stemkowski, S.A., Lin J., and Yang G. (April 2007) Assessing Adherence to the American College of Chest Physicians’ (ACCP) Recommendations for Thromboprophylaxis in Hospitalized Acute Medical Patients, Society of General Internal Medicine (SGIM) 30th Annual Meeting; Oral Presentation.

373.   Ferrufino, C., Lin J. and Hussein M. (April 2007)  Inpatient use of low molecular weight heparin (LMWH) reduces hospital-based treatment costs associated with venous thromboembolism (VTE) prophylaxis, Society of General Internal Medicine (SGIM) 30th Annual Meeting.

374.   Amin, A., Stemkowski, S.A., Lin J., and Yang G. (Feb. 2007) Improving Preventive Care: Assessing Adherence To The Sixth American College Of Chest Physicians’ Recommendations For Thromboprophylaxis In At-Risk Cardiovascular And Stroke Patients In Us Hospitals, American Federation for Medical Research (AFMR), 2007 Western Region Meeting.

375.   Amin, A., Stemkowski, S.A., Lin J., and Yang G. (Feb. 2007) Improving Preventive Care: Assessing Adherence To The Sixth American College Of Chest Physicians’ Recommendations For Thromboprophylaxis In At-Risk Cardiovascular And Stroke Patients In Us Hospitals, American Federation for Medical Research (AFMR), 2007 Western Region Meeting; Oral Presentation.

376.   Spyropoulos, A. and Lin J.  (Dec. 2006) Economic burden of venous thromboembolism from a health plan perspective across the USA, 41st American Society of Health-system Pharmacy (ASHP) Midyear Clinical Meeting and Exhibition

377.   Amin, A., Stemkowski, S.A., Lin J., and Yang G. (Dec. 2006) Thromboprophylaxis in US hospitals: adherence to the sixth American College of Chest Physicians’ recommendations for at-risk medical and surgical patients. 41st American Society of Health-system Pharmacy (ASHP) Midyear Clinical Meeting and Exhibition

378.   Amin, A., Stemkowski, S.A., Lin J., and Yang G. (Nov. 2006) Thromboprophylaxis compliance in U.S. hospitals: adherence to the sixth American College of Chest Physician’s recommendations for at-risk medical patients; American College of CHEST Physicians (ACCP) 2007  Meeting, Abstracts 2006 130: 87S-c; Oral Presentation.

379.   Spyropoulos, A. and Lin J.  (Nov. 2006) Hospital readmission and economic burden of venous thromboembolism: from a health plan perspective; American College of CHEST Physicians (ACCP) 2007  Meeting, Abstracts 2006 130: 260S-a.

380.   Yu, H., Dylan, M.L., Lin J., and Dubois, R.W., (May 2006) Prophylaxis of Venous Thromboemblism: Do Providers Follow Guidelines?  7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, sponsored by the American Heart Association (AHA) /American Stroke Association.